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ABSTRACT
Mammalian iron homeostasis is maintained by an intricate network of diverse proteins 
that constantly survey systemic iron levels and carefully regulate the uptake of iron from 
the diet.  Control of this uptake is critically important because once iron is absorbed, 
mammals have no regulated mechanism for its removal.  The portal through which iron 
enters the body is ferroportin, a multipass membrane protein expressed on the basolateral 
membrane of epithelial cells in the duodenum.  The iron export function of ferroportin is 
primarily regulated by the serum peptide hormone hepcidin, which is secreted from the 
liver when systemic iron levels are high.  Hepcidin acts as a negative regulator of iron 
uptake by binding to ferroportin at the cell surface and inducing its internalization and 
degradation. Genetic defects in ferroportin, hepcidin, or the proteins involved with 
sensing systemic iron levels lead to iron overload diseases known as hereditary 
hemochromatosis.  Using the tools of biophysics and cell biology, we sought to study 
ferroportin and its interaction with hepcidin in order to better understand this critical 
bottleneck in iron uptake and how genetic defects within ferroportin might lead to 
disease.  We developed the first protocols for the overexpression, detergent-solubilization, 
and purification of recombinant ferroportin.  We determined that detergent-solubilized 
ferroportin is a monomer capable of binding hepcidin in vitro.  We characterized the 
expression and subcellular localization of ferroportin in mammalian tissue culture and 
determined that both the amino- and carboxy-termini of ferroportin are cytosolic.  We 
developed cell-based assays for the hepcidin-induced internalization of ferroportin and 
used these to characterize the route of internalization from the plasma membrane through 
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early endosomes to degradative lysosomal compartments.  Using live-cell imaging 
techniques, we showed that this internalization depended on intact microtubules.  We 
expanded this cell-biological study to include sixteen disease-related ferroportin mutants 
and reported that each mutant was expressed on the plasma membrane like wild-type 
ferroportin, but that only a subset of the mutants were capable of being internalized by 
hepcidin.  These studies form a foundation for future biophysical and cell-biological 
studies of ferroportin function.   
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Chapter 1:
Introduction
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INTRODUCTION
Iron's Biological Importance
Life, as we know it, depends on iron.  Its relative abundance on Earth, coupled with its 
capacity to facilitate the rapid transfer of electrons and perform redox chemistry under 
physiological conditions has led to its incorporation in many important biological 
pathways.  The roles that iron plays in the fixation of nitrogen, oxidative phosphorylation, 
and the transport of oxygen in higher organisms are briefly highlighted below.   
All life relies on the fixation of nitrogen (N2), the relatively  inert atmospheric gas, to the 
more chemically reactive ammonia (NH3).  This reduction is catalyzed by 
microorganisms harboring the enzyme nitrogenase (Rees and Howard 2000). 
Nitrogenase is a metalloenzyme complex that utilizes the precise redox properties of iron 
(contained within various iron-sulfur clusters) to coordinate the iterative passage of 
electrons from donors to the nitrogenase active site (Tezcan et al. 2005).  Without these 
microorganisms and their iron-containing nitrogenase enzymes, the nitrogen cycle, upon 
which all life depends, would not be maintained.  Furthermore, higher organisms depend 
on iron for the electron transport central to the redox chemistry of aerobic respiration.  As 
was the case with nitrogenase, the transfer of electrons by proteins in the aerobic 
respiration chain of oxidative phophorylation is facilitated by iron.  Each of the integral 
membrane protein complexes I through IV as well as the soluble enzyme cytochrome C 
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utilize iron in the form of iron-sulfur clusters and/or iron-containing heme groups to carry 
out this electron transfer (Hatefi, 1985).  Other important iron proteins include those 
involved in the transportation of O2 to the sites of respiration, such as hemoglobin and 
myoglobin. These proteins utilize iron coordinated by a porphyrin ring heme moiety.  In 
the case of hemoglobin, this large iron-containing hydrophobic ring system is used to 
bind O2 in the capillaries of the lungs and then release it in the deoxygenated capillaries 
of the extremities.  The affinity switch that iron-bound heme exhibits for O2, within the 
proteinaceous context of hemoglobin, makes it  particularly useful for O2 transport 
proteins in the many organisms employing aerobic respiration in tissues too deep for 
diffusion alone to meet the O2 need.   
In each of these examples, iron plays a critical role in the function of proteins necessary 
for life, however, in each of these examples iron is also sequestered in a heme or iron-
sulfur cluster moiety.  In addition, organisms have evolved complicated and diverse 
mechanisms to regulate the uptake, transport, and storage of iron.  It is thought that 
purely  ionic iron is rarely  (if ever) observed in healthy organisms, and extreme care is 
taken to ensure that ionic iron is carefully chaperoned while in transit to more permanent 
cellular and enzymatic locales.  These intricate mechanisms of sequestration, some of 
which will be described further below, are partially  due to the low solubility of ferric 
iron, but also due to the high reactivity  of ionic iron, particularly  its ability  to promote the 
creation of organic free-radicals through Fenton chemistry  (Halliwell and 
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Gutteridge, 1990).  Free radicals are highly reactive species and have been shown to 
damage lipid bilayers, DNA, and proteins (Halliwell and Gutteridge, 1990).  
Iron Uptake
In humans, the regulation of iron homeostasis is tightly  controlled at both systemic and 
cellular levels.  Dietary iron uptake is tightly controlled at the brush border of the 
duodenum portion of the proximal small intestine (figure 1.1).  Dietary iron can be 
absorbed in ionic form by the divalent metal transporter 1 (DMT1, also called NRAMP2 
and DCT1) (Fleming et al. 1997; Gunshin et al. 1997), or by an unidentified heme 
importer.  DMT1 is a proton symporter that utilizes the pH gradient between the slightly 
basic pH of the cytoplasm and the acidic pH of the duodenum to drive the transport of 
Fe2+ and other divalent metal ions (Gunshin et al. 1997).  The vast majority of dietary 
ionic iron is in the ferric state (Fe3+).  Prior to import, these ions are reduced to the 
ferrous state (Fe2+) by  the integral membrane protein ferroreductase duodenal cytochrome 
b (Dcytb) (McKie et al. 2001) and perhaps STEAP3 (Ohgami et al. 2006).  Once Fe2+ is 
transported across the gut-facing apical membrane of the enterocyte, it enters the so-
called labile iron pool (figure 1.1).  Little is known about the iron in this pool. 
Presumably, these highly  reactive ions in this labile pool are chaperoned by  soluble 
carriers to prevent dangerous Fenton chemistry.  From this pool, ionic iron can be 
incorporated into ferritin for long-term storage or it can be exported into the circulation. 
Ferritin, the long-term iron storage protein, is a hetero-oligomeric protein complex 
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containing 24 copies of L- and/or H-ferritin monomers (Theil, 1987).  Each fully 
assembled ferritin can store ~4500 iron atoms (Theil, 1987).  In times of iron need, 
ferritin can be disassembled and its iron released into the labile pool.  In these duodenal 
enterocytes, iron not destined for storage can be transported across the basal membrane 
into the bloodstream through ferroportin (Fpn; figure 1.1) (Abboud and Haile 2000; 
Donovan et al. 2000; McKie et al. 2000).  Fpn is an integral membrane iron exporter, 
although little is known about the specifics of how it functions.  Some details, such as 
whether the process is driven by  active transport or passive diffusion, the identification of 
the pore-forming amino acids, the oligomeric state of the functional transporter, and the 
details of its ion selectivity, are unknown.  It has been suggested by  some experiments 
that this transport is dependent on the extracellular copper-containing iron-oxidase 
ceruloplasmin (Jeong and David 2003; McKie et al. 2000).  Ceruloplasmin is an 
abundant serum protein and can also be expressed as a GPI-linked splice variant in some 
cell types, where it  has been shown to interact functionally  and physically with Fpn 
(Jeong and David 2003).  Hephaestin, an integral membrane protein homologue of 
ceruloplasmin expressed on the basal membrane of duodenal enterocytes, has also been 
implicated as a copper-containing iron-oxidase that  may also interact with ferroportin 
(Vulpe et al. 1999). After Fe2+ has traveled across the basal membrane through 
ferroportin and has been oxidized to Fe3+, it is bound by the soluble serum protein 
transferrin (Tf) (Andrews 2008). Tf is a monomeric protein containing two iron-binding 
sites, each of which can accommodate a single Fe3+ ion. Iron-loaded Tf (Fe-Tf) is the 
primary source of iron for most cell types, and is taken up by cells in need of iron through 
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the well-characterized transferrin-transferrin receptor (TfR1) iron-uptake pathway (figure 
1.1) (Andrews 2008). 
Unlike iron uptake, which is highly regulated, there is no known regulatory mechanism 
for the excretion of iron in humans.  This implies that the integrity  of iron homeostasis 
for a given individual depends entirely on the proper regulation of iron uptake.  Iron is 
primarily  lost through the routine sloughing of epithelial cells in the gastrointestinal tract, 
blood loss, and menstruation in females.  These losses are balanced by a dietary 
absorption of up to approximately one milligram of iron per day (Sayers et al. 1994), 
however this uptake can be greatly increased, with 20–40 milligrams of iron absorbed per 
day in some cases of induced anemia and pregnancy (Finch, 1994).  As will be seen 
below, this absorption is tightly regulated at both the cellular level of the enterocyte and 
the systemic level of the individual.  Defects in this regulatory network lead to iron 
disorders, primarily  a class of iron overload diseases collectively known as hereditary 
hemochromatosis.  
Regulation of Iron Uptake
Duodenal enterocytes have a short life span.  A typical cell differentiates as an enterocyte 
in the villus crypt and matures as it migrates up to the tip  of the villus, where it is 
eventually sloughed off into the lumen of the intestine within a few days (Roy and Enns 
2000).  Any iron acquired by  an enterocyte through DMT1 or the heme importer must be 
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exported through Fpn into the serum before this apoptotic sloughing takes place, or that 
iron will not be a part of the long-term body iron store.  This mechanism allows for the 
absorption of multiple iron sources into the brush border cells through various import 
proteins, but allows for the regulation of a single protein, Fpn, as the bottleneck for 
systemic iron uptake.  There are at least two mechanisms for the regulation of Fpn 
expression, an iron responsive element (IRE)-based regulation of the mRNA transcript 
resulting in more or less Fpn translated by the ribosome, and a post-translational control 
where a 25-residue serum peptide known as hepcidin-25 (also known as LEAP-1) binds 
to surface-localized Fpn causing its internalization and degradation.
The significance of the IRE-based regulation of Fpn in vivo is poorly  understood (figure 
1.2). The identification of Fpn revealed an IRE in the 5´ untranslated region (UTR) of the 
Fpn transcript (Abboud and Haile 2000; McKie et al. 2000).  It was shown that this 
sequence is capable of binding to the iron regulatory proteins IRP1 and IRP2 in gel shift 
assays (McKie et al. 2000), and that this sequence has an iron-dependent effect on the 
expression of a luciferase reporter in vitro (Abboud and Haile 2000).  The functional role 
in translational regulation that this sequence plays in vivo has been the subject of some 
debate (Abboud and Haile 2000; Frazer et al. 2003; Lymboussaki et al. 2003; Rolfs et al. 
2002), however the finding that autosomal dominant iron overload can occur due to a 
mutation in the 5´ UTR of Fpn suggests that it  has an important function in vivo (Liu et 
al. 2005a).   This argument was further bolstered with a recent report in a murine model 
lacking IRP expression in the intestine (Galy et al. 2008).  Using a mouse line harboring 
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a cre/lox recombinase approach for the intestine-specific ablation of IRP1 and IRP2, Galy 
et al. reported that these pups showed severe growth defects and died before weaning 
(Galy et al. 2008).  They also reported the duodenal enterocyte protein expression levels 
were extremely low for DMT1 and TfR1, but extremely  high for Fpn and ferritin (Galy et 
al. 2008).  Whereas the DMT1 protein expression was correlated with a concomitant 
decrease in DMT1 transcript levels, the elevated Fpn protein expression was in the 
presence of similar Fpn mRNA levels and elevated hepcidin levels, strongly  suggesting 
that the cellular IRP/IRE expression control mechanism can overpower or override the 
hepcidin control mechanism for the expression of Fpn in enterocytes (Galy et al. 2008).
The regulation of Fpn cell-surface expression, and thus iron uptake, by the peptide 
hormone hepcidin is now well recognized as a central theme in iron homeostasis 
(Andrews 2008; Brissot et al. 2008; Darshan and Anderson 2009; Ganz 2008; Nemeth 
2008).  The hepcidin gene encodes an 84-residue pre-protein (Krause et al. 2000; Park et 
al. 2001).  Once expressed, the pre-protein can be processed by intracellular proteases 
cleaving off the amino-terminal ~60-residue and resulting in stable 20-, 22-, or 25-residue 
peptides (Park et al. 2001).  These peptides contain several positively charged residues 
and 8 cysteines (Krause et al. 2000; Park et al. 2001).  The solution structure of synthetic 
hepcidin-20 and hepcidin-25 revealed that the final folded conformation has four 
intramolecular disulfide bonds and the overall fold is composed of a beta-ribbon hairpin 
(Hunter et al. 2002). It has been suggested that these disulfides are not all present in the 
mature hepcidin in vivo, and that some of these cysteines may be involved in chelating 
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cationic metal ions such as copper or iron (Farnaud et al. 2006; Farnaud et al. 2008). 
Hepcidin-25 is the only  version capable of binding and causing the internalization and 
destruction of Fpn (Nemeth et al. 2004b).  It is unclear if hepcidin-20 and hepcidin-22 
have functional roles in vivo.  The primary site of hepcidin production is the liver, 
however hepcidin expression has been observed in other tissues, including adipose tissue, 
heart, lungs, spinal cord, and stomach (Bekri et al. 2006; Krause et al. 2000; Park et al. 
2001; Pigeon et al. 2001). Hepcidin is also present in the urine, but whether hepcidin 
levels in the urine are a good measure of serum hepcidin levels is currently unclear (De 
Domenico et al. 2008).  Techniques have been developed for the determination of 
hepcidin concentration in both blood and urine (De Domenico et al. 2008; Kemna et al. 
2005b).
The main site of systemic iron sensing is the liver.  Hepatocytes involved in this process 
employ an intricate network of proteins to sense body iron stores and/or body iron need 
in order to respond appropriately.  While many of the proteins involved in this network 
have been identified and some critical work in the field has recently been reported, the 
exact picture of how these cells respond to systemic iron levels is not  fully  understood. 
Generally, it is known that high iron levels and inflammation induce the expression and 
secretion of hepcidin into the blood, whereas low iron levels, erythropoiesis, and hypoxia 
act to repress hepcidin expression (Darshan and Anderson 2009).  The molecular 
pathways that integrate these signals are poorly understood, but several recent reports 
have made significant progress elucidating the roles that some members of this network 
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play  (figure 1.3).  There are at least two signaling pathways that up-regulate the 
transcription of the hepcidin gene—the bone morphogenetic growth factor protein (BMP) 
receptor complex pathway and the IL-6 receptor pathway, and at least one pathway that 
acts to repress hepcidin expression—the hypoxia-inducible factor (HIF) pathway (figure 
1.3).  These will be discussed below.
Regulation of Hepcidin Expression
The BMP receptor pathway had been previously shown to play important roles in the 
differentiation and maintenance of certain stem cell lines (Wagner 2007), as well as in the 
post-natal development of bone growth (Chen et al. 2004), however the discovery of its 
involvement in the up-regulation of hepcidin came as a surprise (Babitt et al. 2006). The 
hepcidin transcript has several candidate BMP-responsive elements ~120–210 base pairs 
upstream of the hepcidin start codon, and it was shown that the cytokines BMPs 2, 4 and 
9 can activate this pathway by  binding to the BMP-receptor in complex with hemojuvelin 
(HJV) (Babitt  et al. 2006).  HJV is a glycophosphatidylinositol (GPI)-linked protein that 
was recently identified and shown to be involved in iron homeostasis by  virtue of the fact 
that mutations in this gene lead to an autosomal recessive form of juvenile iron overload 
(Type 2 hereditary hemochromatosis) (Papanikolaou et al. 2004).  HJV can be cleaved 
from the membrane by furin-like proteases or by  matriptase-2, and this soluble form of 
HJV is capable of repressing the BMP-receptor pathway by competing for receptor 
binding with GPI-linked HJV, when exogenously  added (Babitt et al. 2006; Lin et al. 
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2005; Silvestri et al. 2008).  The role of soluble HJVs cleaved by either furins or 
matriptase-2 in vivo is unclear.  The activation of this receptor complex initiates a signal 
transduction cascade by phosphorylating R-SMADs. Phosphorylated R-SMADs bind to 
SMAD4 and localize to the nucleus where the complex acts as a transcription factor to 
promote transcription of hepcidin pre-protein mRNA (Babitt et al. 2006).  Mice deficient 
for this signaling pathway, using a cre/lox targeted-disruption of SMAD4 expression in 
the liver, displayed extremely reduced hepcidin expression, increased expression of the 
Fpn and DMT1 in the intestine, and tissue specific iron overload in liver, pancreas, and 
kidney  (Wang et al. 2005).  Wang et al. also showed that hepcidin expression was not 
induced by iron overload or by the addition of BMP or IL-6 in these mice (Wang et al. 
2005).  Reports of preliminary  data suggesting that HFE and transferrin receptor 2 (TfR2) 
also contribute to the BMB/SMAD signaling pathway by binding to HJV have recently 
emerged (Ganz 2008; Nemeth 2008).  These reports, in conjunction with recent  data 
suggesting that HFE and TfR2 act as iron sensors (Goswami and Andrews 2006; Johnson 
and Enns 2004; Robb and Wessling-Resnick 2004), could explain how iron sensing ties 
into a signal transduction pathway regulating hepcidin expression in hepatocytes. 
Briefly, HFE is a ß2-microglobulin-associated MHC class I homologue, which competes 
for the Tf binding site on TfR1 (Feder et al. 1996; Lebron et al. 1998).  TfR2, like TfR1, 
is capable of binding and internalizing iron-loaded transferrin, however unlike TfR1 its 
expression is restricted to only a few tissue types, with the major site of expression being 
the liver (Kawabata et al. 1999).  As will be described in further detail below, defects in 
HFE and TfR2 lead to hereditary hemochromatosis (HH) types I and III, respectively.
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IL-6 is a serum cytokine secreted under conditions of inflammation and infection and 
binds to cells expressing the IL-6-receptor, thus activating the JAK/STAT signaling 
cascade (Murray 2007). There is a STAT-3-responsive element ~70 base pairs upstream 
of the hepcidin gene, and it has been shown that the intravenous administration of IL-6 
will induce the expression of hepcidin and reduce serum iron levels within a few hours 
(Nemeth et al. 2004a; Wrighting and Andrews 2006).  Similarly, lipopolysaccharide 
injection in humans shows a correlation between a rise in IL-6 concentration and a rise in 
urinary  hepcidin along with a drop in serum iron (Kemna et al. 2005a).  The up-
regulation of hepcidin expression under inflammatory conditions has been shown to be 
similarly  high as wild-type in mice with HFE and TfR2 knockouts, thus these genes are 
not required for the activation of this pathway (Frazer et al. 2004; Lee et al. 2004).  The 
lack of IL-6-induced hepcidin expression in BMP-signaling-deficient mice with liver-
specific SMAD4 ablation, suggests that the BMP/SMAD and IL-6/JAK/STAT pathways 
converge (Wang et al. 2005).
Hypoxia has been shown to down-regulate hepcidin expression in vitro in the HepG2 
hepatic cell line and in vivo in hypoxic mice (Nicolas et al. 2002).  Initial clues pointed to 
the hypoxia-inducible factor (HIF) transcriptional regulatory  complex HIF-1 as the 
pathway responsible for this regulation of hepcidin by a study in mice with a liver-
specific disruption of a gene for a member of the protein complex involved in 
inactivating HIF-1, the von Hippel-Lindau (VHL) gene (Peyssonnaux et al. 2007).  The 
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authors showed that these mice, which constitutively expressed HIF-1 in liver, had a 
suppressed hepcidin expression phenotype and furthermore, went on to show that  HIF-1 
is capable of binding to the hepcidin promoter (Peyssonnaux et al. 2007).  A recent study 
in HepG2 cells reports evidence that  this suppression of hepcidin expression under 
hypoxia is independent of HIF-1, suggesting that more work will be required to fully 
elucidate this pathway (Choi et al. 2007).
Erythropoiesis, the production of red blood cells, requires a great deal of iron and leads to 
an increase in iron need, and thus a decrease in hepcidin production.  Several studies have 
focused on determining the molecular basis for this regulation (Pak et al. 2006; Vokurka 
et al. 2006), but no pathway has been fully revealed.  It was shown that serum from 
patients with ß-thalassemia, where erythropoiesis is up-regulated to account for a genetic 
deficiency in hemoglobin production, was able to suppress hepcidin expression in HepG2 
cells suggesting an unidentified component of serum, up-regulated in ß-thalassemia, 
could induce this hepcidin repression despite the associated anemia (Kemna et al. 2008). 
An additional study on a patient group with thalassemia intermedia showed that before 
transfusion, patients have inappropriately  low urinary hepcidin levels (Origa et al. 2007). 
A comparative analysis of the erythroblast transcriptome profiles between controls and 
patients with ß-thalassemia revealed an over-expression of growth differentiation factor 
15 (GDF15) in the thalassemic group (Tanno et al. 2007).  They found that  adding 
GDF15 to serum would recapitulate hepcidin repression and that depletion of GDF15 
would partially  recover hepcidin expression in primary human hepatocytes (Tanno et al. 
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2007).  Determining whether GDF15 is the sole erythropeoitic hepcidin regulator or not 
will require further investigation.  
Genetic Diseases of Iron Homeostasis
Genetic defects in this network of proteins involved in the regulation of iron homeostasis 
leads to iron imbalance in the form of iron overload, known as hereditary 
hemochromatosis (HH), or insufficient iron, known as anemia (table 1.1).  Both types of 
disorders have numerous causes.  Anemias can be caused by  an inadequate supply of 
dietary iron, extensive blood loss, as well as by a slew of genetic diseases.  Some iron 
homeostatic disorders are caused by defects in hemoglobin synthesis and erythropoiesis, 
such as the thalessemias, sickle cell anemia, and diseases of bone marrow failure.  Other 
forms of genetic iron imbalance lead to a so-called iron-loading anemia.  Some of these 
include aceruloplasminemia, hypotransferrinemia (also known as atransferrinemia), 
anemia of chronic inflammation (also known as anemia of chronic disease), and iron-
refractory iron-deficiency anemia.  Aceruloplasminemia is caused by a deficiency of the 
serum iron reductase ceruloplasmin, and is characterized by a serum iron deficiency with 
iron loading in the liver and brain (Harris et al. 1995).
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Table 1.1. Genetic diseases of iron homeostasis
Gene Associated Disease Inheritance Disease Summary
Ceruloplasmin aceruloplasminemia autosomal recessive
ceruloplasmin deficiency leading to low 
blood iron levels and iron accumulation 
in liver and brain  
Ferroportin type IV hemochromatosis or ferroportin disease
autosomal 
dominant
presents as either anemia associated 
with iron-loading in macrophages or as 
iron overload in blood and liver
Hemoglobin sickle cell anemia autosomal recessive
hemoglobin defects cause formation of 
malformed red blood cells, which can 
lead to capillary obstruction, anemia, 
and other complications
Hemoglobin thallassemias autosomal recessive
low hemoglobin expression levels lead 
to anemia
Hemojuvelin type II hemochromatosis or juvenile hemochromatosis
autosomal 
recessive
severe iron overload in blood and liver, 
presenting in the 2nd or 3rd decade
Hepcidin type II hemochromatosis or juvenile hemochromatosis
autosomal 
recessive
severe iron overload in blood and liver, 
presenting in the 2nd or 3rd decade
HFE type I hemochromatosis autosomal recessive
accumulation of iron in blood and liver, 
presenting in 4th or 5th decade
Transferrin hypotransferrinemia autosomal recessive
transferrin deficiency leading to anemia 
and iron overload in liver and heart, 
presenting in 1st decade
Transferrin 
Receptor 2 type III hemochromatosis
autosomal 
recessive
accumulation of iron in blood and liver, 
presenting in 4th or 5th decade
Much like hereditary anemias, hereditary iron overload or hereditary  hemochromatosis 
can have many  causes.  Defects in the expression and function of HFE, hemojuvelin, 
TfR2, hepcidin, and ferroportin all lead to various types of HH.  All of these genes have 
been discovered within the last 15 years, and as each new gene was discovered and its 
corresponding disease characterized, our understanding of iron homeostasis broadened. 
Various schemes for the classification of known HHs have been proposed based on the 
chronology  of identification (Bomford 2002; Camaschella et al. 2002), pathophysiology 
(Pietrangelo 2007), or groupings related to the regulation of hepcidin expression 
(Andrews 2008).  While the latter two grouping schema are very informative and 
potentially helpful toward understanding themes in iron disease, the former will be used 
here below to explain the pathologies of HH.
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The first HH characterized at the molecular level was HFE-related HH, or type I HH. 
Type I HH is an autosomal recessive disease where patients are homozygous for the 
mutant C282Y HFE allele (Feder et al. 1996).  The HFE gene was identified in 1996 by 
an extensive sequencing and analysis of chromosomal regions proximal to the major 
histocompatibility complex (MHC) in patients with HH (Feder et al. 1996).  They 
identified HFE (then called HLA-H) as an MHC class I homologue and identified the 
C282Y mutation in 83% of their 178 HH patient pool (Feder et al. 1996).  Another 
mutation, H63D HFE, is also a clinically relevant HH mutant, however it  rarely  leads to 
HH unless paired with a C282Y allele to form a so-called C282Y/H63D compound 
heterozygote (Ayonrinde et al. 2008).  Like classical MHC class I proteins, HFE folds as 
an obligate heterodimer with the soluble protein ß2-microglobulin (ß2M) as a light chain. 
Subsequent analysis showed that cysteine 282 is involved in a disulfide bridge in the α3 
domain of the HFE heavy chain, thus the C282Y mutation disrupted HFE's ability  to fold 
and complex with ß2M, preventing its presentation on the cell surface (Feder et al. 1997). 
Structural analysis of HFE revealed that the canonical binding cleft is present, but too 
narrow to accommodate a peptide, as observed in classical MHC class I structures, which 
play  a critical role in the immune system by presenting peptide antigens to T cells 
(Lebron et al. 1998).  To date, type I HH is the most prevalent form of HH worldwide, 
and in comparison to HH types 2–4, it  has been the subject of the most extensive 
analyses.  One such analysis studying HFE alleles in northern European populations 
showed that C282Y/C282Y, C282Y/wild-type, and C282Y/H63D were present in the 
population at frequencies of 0.3%–0.5%, 10%–40%, and 2%–4%, respectively (Adams et 
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al. 2005; Olynyk et al. 1999). The penetrance for type I HH in individuals homozygous 
for the C282Y HFE mutation can be as low as 28.4% for men and 1.2% for women 
(Allen et al. 2008). Affected patients show systemic iron loading leading to organ 
damage, morbidity and mortality.  Iron overload in these patients is typically  a slow 
process and often presents in the fourth or fifth decade of life, with initial iron overload in 
the liver parenchyma followed by iron loading in the heart, pancreas and/or the joints. 
Type I HH is a progressive disease, and if untreated, this overload can result in hepatic 
cancer, organ failure, and death.  Even though HFE has been shown to interact with a 
number of proteins involved in iron homeostasis, the molecular basis for this disease has 
been difficult to fully  characterize.  For instance, HFE has been shown to bind TfR1 
(Feder et al. 1998; Lebron et al. 1998), that the HFE binding site on TfR1 overlaps 
significantly but is not identical with the Tf binding site (Bennett et al. 2000; Giannetti et 
al. 2003), and that Tf and HFE directly compete for TfR1 binding at the cell surface 
(Giannetti and Björkman 2004).  An interaction between HFE and the TfR1 homologue, 
TfR2, was initially  hypothesized, however in vitro binding analyses between soluble 
ectodomains of HFE and TfR2 were shown to not interact (West et al. 2000).  Further 
studies using transfected versions of full-length HFE and TfR2 expressed on the cell 
surface of several different cell types have shown that HFE does in fact  interact with 
TfR2, and that this binding is in competition with TfR1 (Goswami and Andrews 2006). 
Recent findings suggest that HFE activates hepcidin expression and that its sequestration 
by binding to TfR1 can prevent this activation (Schmidt et al. 2008).  It has been 
suggested that this dynamic interplay  between HFE, TfR1, TfR2, and Fe-Tf may be the 
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main mechanism by which hepatocytes sense body iron stores (Darshan and Anderson 
2009; Nemeth 2008).  HFE's role as a member of the putative iron sensor will require 
further work to fully establish.  Another report has shown that HFE inhibits iron uptake 
by down-regulation of Zip14, a proposed iron importer (Gao et al. 2008), though the 
importance of this regulation is unclear, as the role of Zip14 in iron homeostasis is not 
well established.  
Another class of HH known as juvenile hemochromatosis or type II HH, has a strong 
iron-overload pathology consisting of cardiopathy, hypogonadism and often skin 
pigmentation presenting in the second or third decade of life (Camaschella et al. 2002; 
Papanikolaou et al. 2004).  The pathology of type II HH is severe, and unless iron levels 
are reduced by phlebotomy, patients typically  die from cardiomyopathy (Camaschella 
1998).  Type II HH is inherited in an autosomal recessive fashion by mutations in either 
the hepcidin (Roetto et al. 2003) or HJV genes (Papanikolaou et al. 2004), though the 
HJV variant appears to be more common (Rivard et al. 2003b).  The mutations identified 
in hepcidin have been point mutations resulting in the introduction of a stop codon or a 
nonsense frame-shift mutation in the pro-hepcidin gene leading to the truncation or 
nonsense expression of the C-terminal sequence of pro-hepcidin (Roetto et al. 2003). 
Mutations in hemojuvelin have typically been missense point mutations resulting in full-
length mutant expression of mutant proteins (Papanikolaou et al. 2004).  Mutations of 
both sorts, in HJV or the hepcidin gene, result in no hepcidin expression, and thus no 
systemic control of iron uptake down-regulation.  
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Type III HH is caused by  mutations in TfR2. Its presentation in affected patients is 
similar to that of HFE-caused type I HH, as is its method of treatment, namely 
phlebotomy.  Type III HH patients have reduced hepcidin levels, despite high serum iron, 
suggesting that  TfR2 is involved in regulating hepcidin expression (Nemeth et al. 2005). 
TfR2 is a homologue of TfR1, and while it has been shown to interact with iron-loaded 
Tf and is capable of facilitating its import, the uptake of iron appears to not be the 
primary purpose for TfR2 (Kawabata et al. 1999).  As described above, TfR2 is now 
thought to interact with HFE at the cell surface (Goswami and Andrews 2006), and 
through the dynamics of the interactions between HFE, Tf, TfR1 and TfR2, it  is thought 
to be involved in the sensing of systemic iron levels (Darshan and Anderson 2009; 
Nemeth 2008).  In addition TfR2 has been shown to localize to lipid raft domains on the 
cell surface by  virtue of its co-localization with caveolin-1 (Calzolari et al. 2006).  This 
same study showed that TfR2 can also initiate signal transduction via the ERK1/ERK2 
and p38 MAPK pathways by  binding iron-loaded Tf at  the cell surface (Calzolari et al. 
2006).  
Type IV HH is an autosomal dominant iron overload disease caused by  point mutations in 
the ferroportin gene, and will be the in-depth subject of the following section.
19
Ferroportin Disease
Type IV HH, also known as ferroportin disease, has been difficult  to characterize due to a 
mixture of phenotypes and variations in how different individuals present  their iron 
loading.  Some individuals present with similar symptoms to type I HH, elevated Tf 
saturation and serum ferritin levels in conjunction with hepatocyte iron deposits 
(Pietrangelo 2004). However, other individuals present symptoms more like those seen in 
iron-loading anemia, including low Tf saturation and serum ferritin levels, but also with 
significant iron loading in macrophages of the liver and spleen (Pietrangelo 2004).  These 
phenotypic differences are easiest  identified early in the disease progression as patients 
with advanced ferroportin disease tend to show iron overload in all repositories (Njajou et 
al. 2002; Pietrangelo et al. 1999).  Both forms of the disease are inherited in an 
autosomal dominant manner, unlike the other main forms of HH.  The reported defects in 
the Fpn gene are almost exclusively missense point mutations within the coding region, 
with one example of a truncation after residue 330 (Lee et al. 2007) and one example of a 
mutation within the 5' untranslated region (UTR) of the Fpn mRNA (Liu et al. 2005a). 
More than 15 distinct mutations in the Fpn gene have been reported, however a lack of 
pedigree analysis and liver biopsies for many of the reported mutants have made it 
difficult to fully characterize this disease.  Reports including patient data for the known 
Fpn mutants include (in order of occurrence within the gene): adenine 117 to guanine in 
the 5' UTR of the Fpn transcript (Liu et al. 2005a); Y64N (Jouanolle et al. 2003; Rivard 
et al. 2003a); A77D (Corradini et al. 2005; De Domenico et al. 2006; Montosi et al. 
20
2001); G80S (Corradini et al. 2005; De Domenico et al. 2006); N144D (Wallace et al. 
2004); N144H (Njajou et al. 2002; Njajou et al. 2001); N144T (Arden et al. 2003); I152F 
(Girelli et al. 2008); D157G (Hetet et al. 2003); ∆V160 (Cazzola et al. 2002; Devalia et 
al. 2002; Roetto et al. 2002; Wallace et al. 2002); N174I (Corradini et al. 2005; De 
Domenico et al. 2006); Q182H (Hetet et al. 2003); L233P (Girelli et al. 2008); Q248H 
(Beutler et al. 2003; Gordeuk et al. 2003); D270V (Robson et al. 2004); G323V (Hetet et 
al. 2003); C326S (Sham et al. 2005); C326Y (Robson et al. 2004); truncation after G330 
(Lee et al. 2007); and G490D (Jouanolle et al. 2003).  Some of the disease-related data 
for the patients described in these reports are summarized in table 1.2.
In an effort to determine the disease-causing defects associated with some Fpn mutations, 
in vitro analyses of these Fpn mutants have been reported (De Domenico et al. 2006; De 
Domenico et al. 2005; Drakesmith et al. 2005; Girelli et al. 2008; Liu et al. 2005b; 
McGregor et al. 2005; Rice et al. 2009; Schimanski et al. 2005), however linking these 
defects to the disease phenotypes for each case in vivo has been difficult.  
The Fpn gene encodes a protein of 562, 570, or 571 amino acids in zebrafish, mouse, or 
human, respectively.  Fpn has been identified in all vertebrate genomes sequenced, and 
thus far it  the only  protein identified as an ionic iron exporter.  Three groups 
independently reported the discovery of Fpn in the year 2000 (Abboud and Haile 2000; 
Donovan et al. 2000; McKie et al. 2000).  Through a positional cloning effort in 
zebrafish, Donovan et al. showed that mutations in the Fpn gene lead to the 
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hypochromatic weh phenotype caused by a lack of iron import (Donovan et al. 2000). 
They  further showed that this mutant phenotype can be rescued by iron-dextran injections 
or by  Fpn-GFP transfection (Donovan et al. 2000).  Using a subtractive cloning strategy 
involving cDNA libraries from wild-type and the hypotransferrinemic hpx mouse, McKie 
et al. identified Fpn and similarly characterized it as an iron exporter in an iron efflux 
assay with Xenopus oocytes (McKie et al. 2000).  A third study  using an mRNA library of 
sequences enriched for IRP1 binding was used to search for novel transcripts involved in 
iron uptake in the murine duodenum (Abboud and Haile 2000).  These studies each 
showed that Fpn is expressed at the site of dietary iron absorption in mammals—the basal 
membrane of the proximal duodenum, as well as other important sites of iron export, 
namely the liver, spleen, and placenta (Abboud and Haile 2000; Donovan et al. 2000; 
McKie et al. 2000).  They  also reported that Fpn is the likely  iron exporter, either directly 
through radioactive iron efflux analyses in microinjected Xenopus oocytes (Donovan et 
al. 2000; McKie et al. 2000) or indirectly by  observing reduced intracellular ferritin 
levels in transfected HEK293T cells (Abboud and Haile 2000).  Fpn is highly  conserved 
between species, with human Fpn sharing 91.2% identity with mouse Fpn and 76% 
identity with zebrafish Fpn, using the ClustalW algorithm (Larkin et al. 2007). 
The transmembrane domain (TM) topology of Fpn protein has been predicted in 
numerous reports ranging from 9 to 12 TMs (Devalia et al. 2002; Donovan et al. 2000; 
Goncalves et al. 2006; Liu et al. 2005b; McKie et al. 2000; Rice et al. 2009), however a 
consensus has emerged where the 12 TM model proposed by Liu et al. based on 
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insertional mutagenesis has now been widely accepted (De Domenico et al. 2008; Liu et 
al. 2005b; Rice et al. 2009).  
The oligomeric state of Fpn has also been the subject of significant debate.  Reports have 
conflicted, with some reporting Fpn as a monomer (Goncalves et al. 2006; Pignatti et al. 
2006; Schimanski et al. 2008) and others reporting it as a dimer/multimer (De Domenico 
et al. 2007b; De Domenico et al. 2005).  Reports from the Kaplan lab have provided 
evidence that differentially tagged Fpns (wild-type-wild-type or wild-type-∆V160) 
interact by co-immunoprecipitation in co-transfected HEK293T cells (De Domenico et al. 
2007b; De Domenico et al. 2005), however similar experiments in another laboratory did 
not reproduce their results (Goncalves et al. 2006).  Furthermore, a report from 
Schimanski et al. cited a lack of evidence for an interaction between differentially  tagged 
wild-type Fpns in a FRET assay, as well as a lack of interaction between differentially 
tagged wild-type and ∆V160 Fpn in a degradation assay, both performed in co-
transfected HEK293T cells (Schimanski et al. 2008).  Proponents of the dimer/multimer 
Fpn model further cite genetic data in murine systems.  For instance, it has been shown 
that mice heterozygous for an Fpn knockout do not show signs of Type IV HH (Donovan 
et al. 2005), which would be expected in heterozygotes if Fpn haploinsufficiency were 
the cause of disease.  They argue that  if Fpn were a dimer, and heterodimers between 
mutant and wild-type Fpn molecules were inactive, then only  25% of dimers would be 
functional and would more convincingly describe the severe phenotype observed in this 
autosomal dominant disease.  The only report of Fpn overexpression and purification has 
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shown that detergent-solubilized Fpn, capable of binding hepcidin-25, is a monomer 
(Rice et al. 2009).  In summary, the oligomeric status of Fpn in vivo is unresolved.  It 
remains possible that Fpn exists in two distinct oligomeric states at different  stages of its 
function and that the discrepancies in the literature reflect a biologically relevant 
oligomeric equilibrium.  
The regulation of Fpn at the cell surface has been more carefully characterized with 
respect to its interaction with hepcidin-25.  As mentioned above, hepcidin is a 25-residue 
peptide expressed in the liver when systemic iron levels are high and secreted into the 
serum where it  can bind Fpn causing its internalization and degradation (Nemeth et al. 
2004b).  The binding of hepcidin-25 to Fpn appears to be facilitated by a 19-residue 
stretch, termed the hepcidin binding domain (HBD), of Fpn's 4th extracellular loop 
between TMs 7 and 8 (De Domenico et al. 2008).  A 19-residue HBD peptide from this 
region was shown to recapitulate the Fpn-hepcidin interaction in an in vitro bead assay 
and that this binding was temperature dependent (De Domenico et al. 2008), as had been 
previously  described (Nemeth et al. 2004b). Interestingly, the HBD contains only one 
position known to cause Type IV HH upon mutation—cysteine 326.  After hepcidin-25 
binds to Fpn, tyrosine 302 or tyrosine 303 are phosphorylated at  the cell surface and 
internalized (De Domenico et al. 2007a).  Upon internalization, Fpn is dephosphorylated 
and ubiquitinated leading to its degradation in lysosomes (De Domenico et al. 2007a). 
The internalization of Fpn has been shown to progress through early endosomal antigen 
1-positive (EEA1-positive) endosomes on its way to lysosome-associated membrane 
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proteins 1 and 2 (LAMP1 and LAMP2) positive compartments in Fpn-GFP-transfected 
HeLa cells (Rice et al. 2009).  Furthermore, the transport of hepcidin-induced Fpn 
internalization was dependent on intact microtubules (Rice et al. 2009).
Fpn's role as a critical bottleneck in iron uptake and in type IV HH make it  an important 
molecule to study.  Further understanding of its function and regulation are needed to 
understand iron uptake and homeostasis, and those insights could lead to advances in the 
treatment of disorders involving the dysregulation of iron intake.
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Figure 1.1. Iron uptake in the proximal duodenum.  Adapted from Kaplan and Kushner 
2000.
27
Figure 1.2. IRE/IRP translational control of proteins in iron homeostasis. Iron responsive 
proteins 1 and 2 (IRP1 and IRP2) bind to iron responsive element (IRE) hairpin loops in 
the untranslated region (UTR) of transcripts when iron levels are low.  The binding of 
IRP to a 5  ´ IRE prevents translation, whereas IRP binding to a 3´ IRE stabilizes the 
transcript and boosts expression.  The effects of the IRE/IRP system are shown for 
ferritin, Fpn, TfR, and DMT1.  Adapted from Muckenthaler et al. 2008.  
28
Figure 1.3. The regulatory network of hepcidin transcription.  Adapted from Darshan and 
Anderson 2009.
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Chapter 2:
Investigation of the Biophysical and Cell Biological 
Properties of Ferroportin, a Multipass Integral Membrane 
Protein Iron Exporter
In this paper we report the over-expression, purification, biophysical, and cell biological 
characterization of recombinant human ferroportin.  Michael Mendez and Craig 
Hokanson brought with them expertise in the expression of membrane proteins using 
baculovirus-infected insect cells and helped get this system started for ferroportin 
expression.  
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Ferroportin is a multipass membrane protein that serves as an iron exporter
in many vertebrate cell types. Ferroportin-mediated iron export is
controlled by the hormone hepcidin, which binds ferroportin, causing its
internalization and degradation. Mutations in ferroportin cause a form of
the iron overload hereditary disease hemochromatosis. Relatively little is
known about ferroportin's properties or the mechanism by which
mutations cause disease. In this study, we expressed and purified human
ferroportin to characterize its biochemical/biophysical properties in
solution and conducted cell biological studies in mammalian cells. We
found that purified detergent-solubilized ferroportin is a well-folded
monomer that binds hepcidin. In cell membranes, the N- and C-termini
were both cytosolic, implying an even number of transmembrane regions,
and ferroportin was mainly localized to the plasma membrane. Hepcidin
addition resulted in a redistribution of ferroportin to intracellular
compartments that labeled with early endosomal and lysosomal, but not
Golgi, markers and that trafficked along microtubules. An analysis of 16
disease-related ferroportin mutants revealed that all were expressed and
trafficked to the plasmamembrane but that somewere resistant to hepcidin-
induced internalization. The characterizations reported here form a basis
upon which models for ferroportin's role in regulating iron homeostasis in
health and disease can be interpreted.
© 2008 Elsevier Ltd. All rights reserved.
Edited by J. Bowie
Keywords: ferroportin; hemochromatosis; hepcidin; membrane protein;
live-cell imaging
Introduction
Hereditary hemochromatosis is an iron overload
disease caused by defects in the regulation of cellular
and systemic iron levels.1,2 One type of hemochro-
matosis, known as type IV hereditary hemochroma-
tosis or ferroportin disease, is caused by missense
mutations in the gene encoding the iron export
protein ferroportin (Fpn, also known as IREG1 or
MTP1; accession number Q9NP59).3 Fpn is a multi-
pass integral membrane protein found in ver-
tebrates.4–6 All cell types that export ionic iron
express Fpn, including duodenal enterocytes, white
blood cells involved in erythrophagocytosis, Kupffer
cells, brain astrocytes, and placental cells.4–7
Although Fpn has been implicated as the iron
exporter in these cells, whether this export process
is active or passive is unknown. Fpn expression
levels are regulated posttranslationally by interac-
tion with hepcidin-25, a peptide hormone8 produced
in the liver9 and secreted into the blood when iron
levels are high.10 Hepcidin binds to Fpn at the cell
surface and is internalized with Fpn.8 In HEK293T
*Corresponding author. E-mail address:
bjorkman@caltech.edu.
Abbreviations used: DM, n-decyl-β-D-maltoside; DDM,
n-dodecyl-β-D-maltoside; SEC, size-exclusion
chromatography; LS, light scattering; RI, refractive index;
GFP, green fluorescent protein; MDCK, Madin–Darby
canine kidney; TM, transmembrane; FSEC, fluorescent
SEC; 3D, three-dimensional; PBS, phosphate-buffered
saline.
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cells, and presumably in vivo, the binding of hepcidin
to Fpn results in the phosphorylation, ubiquitina-
tion, and internalization of Fpn,11 ultimately leading
to its degradation in lysosomes.8
Ferroportin disease usually presents as one of
two phenotypes—one in which patients display
macrophage iron loading, low transferrin iron
saturation, and high serum ferritin levels and
another in which patients display hepatocyte iron
loading and high transferrin saturation. A number
of point mutations in the Fpn gene have been
identified.3,12–25 Recent in vitro studies focused on
characterizing subsets of these mutants in an effort
to reveal the nature of the defects caused by the
disease-causing Fpn mutations.26–31
Here, we report recombinant expression of Fpn in
insect cells and a biophysical characterization of
purified detergent-solubilized Fpn, including a
determination of its oligomeric state and its binding
interactions with different forms of hepcidin. We
also compared the expression and subcellular
localization of wild-type and mutant Fpn's in the
presence and in the absence of hepcidin and studied
wild-type Fpn-trafficking using live-cell imaging.
Results
Expression and characterization of Fpn
expressed in insect cells
Human, mouse, and zebrafish Fpn's were
expressed in baculovirus-infected insect cells.
Expression constructs were created encoding
tagged versions of full-length human, mouse, and
zebrafish Fpn's. Addition of an N-terminal Rho tag,
the first 20 aa of bovine rhodopsin, which boosts
expression levels for some eukaryotic membrane
proteins,32 was required for detectable expression
in insect cells. C-terminal FLAG and/or His tags
were added to aid in affinity purification, resulting
in Rho-Fpn-His-FLAG and Rho-Fpn-His constructs.
Insect cell membranes were analyzed by fractiona-
tion analysis using a discontinuous sucrose
gradient,33 and Fpn was found in the plasma
membranes of infected cells (data not shown).
Several detergents could be used to solubilize Fpn
from isolated plasma membranes, including [3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane-
sulfonate (Chaps), 6-cyclohexyl-1-hexyl-β-D-malto-
side (CYMAL-6), lauryldimethylamine-N-oxide
(LDAO) and polyoxyethylene(8)dodecyl ether
(C12E8), n-decyl-β-D-maltoside (DM), and n-dode-
cyl-β-D-maltoside (DDM)]. Human Rho-Fpn-His
and Rho-Fpn-His-FLAG were purified in DM or
DDM using affinity chromatography with yields of
∼50–100 μg of Fpn per liter of insect cell culture.
Similar results were obtained for mouse and
zebrafish Fpn's, but the analyses reported in the
remainder of this study were conducted using
human Fpn. More highly purified Fpn was
obtained from the Rho-Fpn-His-FLAG construct
using a two-step His/FLAG affinity purification
protocol. SDS-PAGE analysis of purified Rho-Fpn-
His and Rho-Fpn-His-FLAG revealed a single
predominant band migrating with an apparent
molecular mass of ∼60 kDa (Fig. 1a). Western
analysis showed this band to be positive for both
the N- and C-terminal tags, thus demonstrating
expression of full-length Fpn (data not shown).
To verify biological activity, we evaluated the
ability of purified detergent-solubilized human Fpn
to bind hepcidin. Rho-Fpn-His was purified from
insect cell membranes in DM or DDM on a cobalt
affinity resin and then captured on a CM5 biosensor
surface with an immobilized anti-Rho antibody.
Hepcidin-25 or a non-Fpn-binding version lacking
the five N-terminal amino acids (hepcidin-20)8 was
injected at 10 μM. In three independent experiments,
we found that ∼10-fold more hepcidin-25 than
hepcidin-20 bound to the Fpn surface (Fig. 1b). In an
attempt to obtain an equilibrium dissociation con-
stant (Kd) for the interaction between Fpn and
hepcidin-25, we performed surface plasmon reso-
nance binding experiments between coupled Fpn
and a dilution series of hepcidin-25 (0.625–10 μM)
(Fig. 1b). While the data did not fit well to a 1:1
binding model, presumably due to complex binding
events related to aggregation of the injected hepci-
din (see Materials and Methods), the results sug-
gested a low micromolar Kd.
Detergent-solubilized Fpn is monomeric
In order to determine the molecular mass and
hence the oligomeric state of purified Fpn, we
performed size-exclusion chromatography (SEC) in
conjunction with multiangle light scattering (LS),
differential refractive index (RI), and ultraviolet
absorption (UV) spectroscopy analysis.34 SEC-LS/
UV/RI can be used to determine the absolute
molecular mass of a protein in complex with non-
UV-absorbing modifiers, such as carbohydrates,
lipids, and detergents.34,35 Purified human Fpn
(Rho-Fpn-His-FLAG) solubilized in DDM was used
for these experiments. The UV chromatogram for
Fpn was observed as a single peak at ∼13.5 mL,
whereas the LS and RI traces were both doublets,
with one peak at∼13.5 mL and another at∼15.5 mL
(Fig. 1c). The first peak in the doublets overlaid with
the UV peak and corresponded to the Fpn–detergent
micelle complex, while the second peak corre-
sponded to free detergent micelles. The free-micelle
peak of DDM detergent gave a calculated molecular
mass of 75.8±6.8 kDa, consistent with the DDM
micelle size measured by the vendor†. Although the
Fpn–detergent peak was not fully resolved from the
DDM free-micelle peak, large regions of each peak
were sufficiently separated and could be selected for
analysis (Fig. 1c). The molecular mass of the Fpn–
detergent complex determined using this method
was 201±18 kDa, with 69.1 ± 6.2 kDa of this
†http://www.anatrace.com
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attributed to protein and 132±12 kDa attributed to
bound detergent plus lipids and/or carbohydrate.
The molecular mass derived for the protein compo-
nent of the Fpn–detergent complex is in agreement
with the predicted molecular mass of 69,015 g/mol
for Rho-Fpn-His-FLAG, thus suggesting that deter-
gent-solubilized Fpn is a monomer.
Topology of Fpn in the plasma membrane
The locations of the N- and C-termini of Fpn have
been the subject of debate, with some studies finding
one or both termini to be extracellular27,28,36 and
others finding one or both termini to be in-
tracellular.26,37,38 In order to resolve this issue, we
expressed N- and C-terminally tagged Fpn [Rho-
Fpn-GFP (green fluorescent protein)] in three mam-
malian cell lines and used confocal immunofluores-
cence microscopy to compare the accessibility of the
tags in permeabilized versus nonpermeabilized cells.
Although the Rho tag was required for expression in
insect cells, we found that Fpn could be expressed in
mammalian cells without this tag, so we evaluated
the location of the C-terminus in independent
experiments. If the N- or C-terminus is extracellular,
we would expect to find no difference in permeabi-
lized versus nonpermeabilized cells when probing
with an antibody against the relevant tag. If a
terminus was intracellular, we would expect to see
antibody staining in permeabilized, but not non-
permeabilized, cells.
Fpn-GFP or Rho-Fpn-GFP constructs were tran-
siently expressed in HEK293T, HeLa, and Madin–
Darby canine kidney (MDCK) cells. Both constructs
Fig. 1. Biophysical characterization of purified Fpn. (a) SDS-PAGE analysis of purified Rho-Fpn-His (estimated to be
∼70% pure) and Rho-Fpn-His-FLAG (estimated to be ∼90% pure) proteins. Samples were run under reducing conditions
in SDS loading buffer without boiling on 15% (Rho-Fpn-His) or 4%–20% (Rho-Fpn-His-FLAG) polyacrylamide gels. (b)
Biosensor analysis of the Fpn–hepcidin interaction. Hepcidin-25 was injected over immobilized Fpn as a series of dilutions
(0.625, 1.25, 2.5, 5.0, 8.0, and 10 μM). Sensorgrams (black lines) are overlaid on the simulated response (red lines) derived
using a 1:1 binding model. The fit of the binding model to the data is poor, perhaps resulting from the presence of
hepcidin-25 aggregates. The inset shows results from injections of 10 μMhepcidin-25 and hepcidin-20. (c) SEC-LS/UV/RI
analysis of DDM-solubilized Fpn. Normalized traces for UV absorbance at 280 nm (red), 90° LS signal (blue), and
differential RI (green) signals are shown. Molecular mass values calculated for the protein–detergent complex (black),
detergent micelle (dark gray), and protein (light gray) are displayed as overlays on the peaks at ∼13.5 and∼15.5 mL, and
the range of calculated molecular masses is projected onto the left and right axes. (d) Comparison of mobility by FSEC for
wild-type Fpn versus disease-related Fpn mutants. Wild-type Fpn and 16 Fpn mutants were transiently expressed as GFP
fusion proteins in HEK293T cells. Whole cell lysates were passed over a gel filtration column, and the migration of each
protein was monitored by fluorescence. Wild-type Fpn-GFP and all the Fpn-GFP mutants exhibited a peak at ∼12 mL,
which was not found in lysates from untransfected HEK293T cells (red curve). The peak at ∼16 mL was found in samples
prepared from both transfected and untransfected cells.
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were used to determine the location of the C-
terminus using a labeled anti-GFP antibody, and the
Rho-Fpn-GFP construct was used to determine the
location of the N-terminus using a labeled anti-Rho
antibody. Full confocal stacks were recorded for
each condition, with representative slices displayed
in Figs. 2 and 3. GFP fluorescence from the C-
terminal tag was visible at the plasma membrane
under permeabilizing and nonpermeabilizing con-
ditions, and it served as a marker for successfully
transfected cells. Antibody staining of the N-
terminal Rho or the C-terminal GFP tag was only
observed under permeabilizing conditions or when
the plasma membrane was compromised by a
visible tear. This result was consistent for both
Rho-Fpn-GFP and Fpn-GFP in three cell lines (Figs.
2 and 3). We conclude that the N- and C-termini of
Fpn are cytosolic in HeLa, HEK293T, and MDCK
cells, implying that Fpn contains an even number of
transmembrane (TM) domains.
Disease-related Fpn mutants behave like the
wild type in detergent and are expressed at the
plasma membrane
To determine if disease-related mutations in Fpn
altered its detergent solubility and oligomeric state,
we expressed 16 Fpn-GFP mutants transiently in
HEK293T cells and compared them with wild-type
Fpn-GFP. Rather than purify each of themutants and
conduct SEC-LS/UV/RI experiments, we used
fluorescent SEC (FSEC), a method to obtain a SEC
profile of a GFP-tagged protein in a complexmixture
of proteins.39 We found that the FSEC traces for Fpn-
GFP and the suite of disease-causingmutant proteins
were similar (Fig. 1d). Given that SEC-LS/UV/RI
analysis demonstrated that wild-type Fpn is well
folded (i.e., it migrates in SEC as a defined peak
outside the void volume) and a monomer (Fig. 1c),
the finding of similar SEC profiles for wild-type and
mutant Fpn's indicates that the mutants were also
well-folded monomers that could be solubilized in
detergent.
We next determined the subcellular localizations
of wild-type and mutant Fpn-GFP proteins
expressed transiently in different cell lines. Expres-
sion of wild-type Fpn-GFP in polarized cells (filter-
grown MDCK cells) revealed that Fpn-GFP was
expressed primarily on the cell surface (Fig. 4).
Expressionwas observed along the entire basolateral
membrane below the tight junctions, but not at the
apical surface, as determined by anti-ZO1 staining of
the tight junctions (data not shown). In a nonpolar-
ized cell line (HeLa), fluorescence for wild-type Fpn-
Fig. 2. Analysis of Fpn mem-
brane topology. Bar represents
10 μm. Rho-Fpn-GFP was transi-
ently expressed in HeLa cells. Fixed
cells were probed against a labeled
antibody against the N-terminal
Rho tag (a) or against the C-terminal
GFP tag (b) under permeabilizing
(+saponin) and nonpermeabilizing
(−saponin) conditions. Similar
results were found for Rho-Fpn-
GFP expressed in HEK293T and
MDCK cells and for Fpn-GFP
expressed in HeLa, HEK293T (Fig.
3), and MDCK cells (data not
shown).
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GFP was found around the entire cell surface as well
as in intracellular compartments (Fig. 2), as pre-
viously described for expression in HeLa and
HEK293T cells.8 Upon treatment with the protein
synthesis inhibitor cycloheximide, a larger propor-
tion of Fpn-GFP localized to the plasma membrane
and the intracellular Fpn-GFP signal that remained
was faint and diffuse compared with the fluores-
cence at the plasma membrane (Fig. 5), suggesting
that much of the intracellular Fpn-GFP signal
observed in untreated cells represented newly
synthesized protein on its way to the cell surface.
The localization of each of the disease-related Fpn
mutants was examined in cycloheximide-treated
HeLa cells (Fig. 5) and in untreated filter-grown
polarized MDCK cells (Fig. 4). Each of the mutants
localized similarly to wild-type Fpn-GFP (i.e., with
little internal fluorescence and a strong cell surface
signal). Evidence for the primarily surface localiza-
tion of Fpn-GFP proteins can be difficult to convey
in two-dimensional images of flat HeLa cells, so we
present side views of cells for all the Fpn mutants
(Fig. 5) and movies of three-dimensional (3D)
reconstructions for selected mutants (Movies S1–
S5). These data suggested that all the disease-related
Fpn mutants examined here trafficked normally to
the plasma membrane.
Effects of hepcidin on disease-related Fpn
mutants
Previous studies demonstrated that wild-type Fpn
is internalized into lysosomes upon treatment with
hepcidin-25.8 To compare the effects of hepcidin on
Fig. 4. Fpn-GFP subcellular localization in MDCK cells. Bar represents 10 μm. Fpn-GFP and disease-related Fpn-
mutants were transiently expressed in filter-grown polarized MDCK cells.
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wild-type and mutant Fpn's, we expressed Fpn-GFP
proteins transiently in HeLa cells, pretreated the
cells with cycloheximide to reduce intracellular
fluorescence, and then incubated them in the
presence or absence of 2 μM hepcidin-25. After 4 h,
the cells were fixed and examined by confocal
fluorescence imaging. Wild-type Fpn-GFP was
internalized in all cells imaged, but the level of
internalization at any tested time point varied from
cell to cell. At the 4-h time point used for this study,
the GFP signal in some cells was observed as fully
internalized puncta, whereas other cells displayed a
portion of their GFP signal at the plasma membrane
(see the two wild-type Fpn-GFP panels in Fig. 5).
The surface signal tended to decrease over time as
the hepcidin-25 incubation progressed (data not
shown). We expect that these differences were due to
varying levels of Fpn-GFP expression from cell to
cell in the transient transfection.
Most of the disease-related Fpn mutants were
internalized upon treatment with hepcidin-25
(Fig. 5), with internalization observed as bright
puncta throughout the cytoplasm. Hepcidin-sensi-
tive Fpn-GFP constructs includedwild-type Fpn and
the A77D, N144D, N144H, N144T, D157G, ΔV160,
N174I, Q182H, Q248H, D270V, and G323V Fpn
mutants. Like wild-type Fpn-GFP, the hepcidin-
sensitive Fpn-GFP mutants displayed a distribution
of internalization completeness, with some cells
within a sample showing residual surface signals.
Fig. 5. Fpn-GFP localization and sensitivity to hepcidin-25. Bar represents 10 μm; the inset is shown at a magnification
of 5×. Fpn-GFP and disease-related Fpn-GFP mutants were transiently expressed in HeLa cells, which were pretreated
with cycloheximide and then incubated for 4 h with or without 2 μMhepcidin-25. Each panel is a representative slice from
a confocal stack. Below each panel is a reconstructed side view for the region in a plane denoted by the thin white line in
the main panel. The side views were elongated by a factor of 2 in the z-direction to facilitate visualization of fluorescence
in these thin cells.
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Representative cells from these experiments can be
found in Fig. 5. The Y64N, G80S, C326S, C326Y, and
G490D Fpn mutants showed no internalized punc-
tum and were therefore classified as resistant to
hepcidin-induced internalization (Fig. 5).
Characterization of hepcidin-induced Fpn
internalization in HeLa cells
To further study the pathway by which Fpn is
internalized upon treatment with hepcidin, we
identified Fpn-positive compartments using anti-
bodies against endosomal and lysosomal markers.
For these experiments, wild-type Fpn-GFP was
transiently expressed in HeLa cells, pretreated
with cycloheximide, and then incubated with
hepcidin-25 for 4 h, as described above. Cells were
fixed and probed with fluorescent antibodies
against the early endosomal marker EEA1, the
lysosomal marker LAMP1 or LAMP2, or a 58-kDa
Golgi-resident protein. Internalized Fpn-GFP
puncta were found to partially co-localize with
EEA1, LAMP1, and LAMP2, but not with the 58-
kDa Golgi marker (Fig. 6).
Hepcidin-induced internalization of Fpn-GFP was
also investigated in live HeLa cells using spinning-
disk confocal microscopy, which enables rapid
image acquisition to monitor dynamic biological
processes.40 Fpn-expressing HeLa cells were grown
in glass-bottomed dishes, and imaging was per-
formed at 37 °C in a temperature-controlled
enclosure. Fpn-GFP-positive intracellular compart-
ments, which were observed within 15 min of
hepcidin addition, were seen to travel throughout
much of the cytoplasm in a relatively random
fashion (data not shown). Over the course of
hours, accumulation of bright puncta in regions
proximal to the nucleus was observed, as seen in the
fixed cell images, which were acquired 4 h after
hepcidin addition (Fig. 5).
When trafficking was monitored for a shorter time
(0.5–5 min), Fpn-GFP compartments traveled in
many directions with no apparent net directionality.
Interestingly, some of the Fpn-GFP-positive com-
partments moved back and forth along what
Fig. 7. Effects of nocodazole on internalized Fpn. Bar
represents 5 μm. Fpn-GFPwas transiently expressed inHeLa
cells, which were pretreated with cycloheximide, incubated
with 2 μMhepcidin-25, and then imaged live in the presence
or absence of 10 μg/mL of nocodazole. GFP-positive
compartments were tracked as described in Materials and
Methods. Tracks throughout a 90-s time course were
overlaid on representative images of an untreated cell (a)
or a nocodazole-treated cell (b).
Fig. 6. Mapping of the intracellular locations of hep-
cidin-internalized Fpn-GFP. Bar represents 10 μm; the inset
is at a magnification of 5×. (a–d) Fpn-GFP was transiently
expressed in HeLa cells, which were pretreated with
cycloheximide and incubated with 2 μM hepcidin-25.
Fixed cells were probed with antibodies against markers
for early endosomes (EEA1; a), lysosomes (LAMP1 and
LAMP2; b and c), and the Golgi (58-kDa Golgi protein; d).
LAMP1 staining adjacent to the Fpn-GFP-positive cell in
(b) represents endogenous LAMP1 from a neighboring cell
that did not express Fpn-GFP.
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appeared to be a track. To determine if the tracks
represented microtubules, we imaged the cells in the
presence and in the absence of the microtubule
depolymerizing agent nocodazole. In the presence
of nocodazole, trafficking of Fpn-GFP-positive
compartments was almost entirely halted (Fig. 7;
Movies S6 and S7). Tracking analyses were per-
formed on N1100 Fpn-positive compartments per
condition, and the disruption of overall trafficking
by nocodazole was evident in terms of a reduction of
mean-square displacement for individual compart-
ments (Fig. 8a) and in a reduction of overall track
displacement length for the full set of tracks (Fig.
8b). In the presence of nocodazole, no compartment
was found more than 0.98 μm from their starting
points, whereas in untreated cells, 178 compart-
ments (15.9%) were located at a distance of 1 μm or
farther from their starting points.
Discussion
Although Fpn plays a key role in the maintenance
and regulation of systemic iron homeostasis, many
of its basic features remain controversial. We sought
to characterize some of the biophysical and cell
biological properties of Fpn using purified deter-
gent-solubilized protein and Fpn expressed in
eukaryotic cells. Here, we report an insect cell
expression system that can be used to produce
recombinant human Fpn for structural and biophy-
sical studies.
The oligomeric state of Fpn has been debated for
several years—the protein has been reported to be a
monomer36,38,41 as well as a dimer/multimer.30,37
Using SEC-LS/UV/RI, a shape- and model-inde-
pendent method to obtain a molecular mass,34 we
determined that purified detergent-solubilized Fpn
is monomeric (Fig. 1c). This result does not explicitly
address the oligomeric state of Fpn in its native
environment of the lipid bilayer. However, in pre-
vious studies of other membrane proteins, including
LacYand GlyT1, the oligomeric state determined for
the purified protein in detergent correlated with the
oligomeric state in the membrane bilayer.42,43 Thus,
although this result cannot rule out a transient
dimerization/multimerization event, it suggests
that homophilic interactions that might exist in the
context of a bilayer are sufficiently weak so as to be
disrupted by a nonionic detergent. A recent report
Fig. 8. Tracking Fpn-GFP-positive compartments in HeLa cells in the presence and in the absence of nocodazole. Cells
were treated and imaged as described in Fig. 7. (a) The mean-square displacement of representative tracks in untreated
(blue) versus nocodazole-treated (red) cells showed that nocodazole treatment produced a marked reduction in Fpn-GFP
trafficking. (b) Track displacements for the set of tracked vesicles in untreated (blue) and nocodazole-treated (red) cells
presented as a histogram.
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showed that a 19-aa peptide derived from an
extracellular loop of Fpn (the hepcidin-binding
domain; residues 324–343) is capable of binding
hepcidin-25 but not hepcidin-20.44 In support of the
contention that purified Fpn monomers are func-
tional, we showed that purified Fpn exhibits
physiologically relevant binding to hepcidin-25 but
not hepcidin-20 (Fig. 1b), suggesting that detergent-
solubilized Fpn effectively presents the hepcidin-
binding domain. Although we were unable to
obtain an accurate Kd for the Fpn–hepcidin-25
interaction, the data suggested a low micromolar
affinity, consistent with the ∼ 0.7 μM IC50 value
obtained in in vitro8 and in vivo experiments in
which a serum concentration of 1.4 μM hepcidin-25
induced a prolonged reduction in serum ferritin
levels.45
The membrane topology of Fpn and the related
issue of howmany TMdomains it contains have also
been the subject of debate. In particular, different
results have been obtained for the location of the Fpn
C-terminus. Fluorescent antibodies against a C-
terminal tag on Fpn have been used to label live
cells in flow cytometry experiments,27,28,36 implying
an extracellular location. Immunofluorescence
microscopy has been used to suggest both an
extracellular36 and an intracellular26,37,38 localization
for the Fpn C-terminus. Our results using two
ferroportin constructs in three mammalian cell
lines strongly support an intracellular location for
the N- and C-termini of Fpn. A recent report may
explain the discrepancy in the studies regarding the
accessibility of the Fpn termini: the C-terminus of
Fpn was found to be normally cytosolic but
accessible to labeled antibodies in nonpermeabilized
cells when the cells were undergoing apoptosis due
to reduced intracellular iron levels.38 Thus, previous
reports of the detection of C- and N-terminal tags in
nonpermeabilized cells may have resulted from
inclusion of apoptotic cells in the analyses.
Fig. 9. Prediction of membrane topology of Fpn. Sequences for full-length human, mouse, and zebrafish Fpn's were
submitted to the TMHMM v2.0 prediction server.46 Each sequence was predicted to contain 12 regions that were 21–23 aa
in length with a significant (N60%) probability of being a TM region (see Materials andMethods). TMHMMpredicted that
the N- and C-termini of Fpn are cytosolic, consistent with our data (Figs. 2 and 3). Highlighted amino acids indicate
positions where disease-related mutations have been identified. Red positions indicate hepcidin resistance, whereas blue
positions indicate hepcidin sensitivity. Only the C326Y and C326S mutations fall in the hepcidin-binding domain
(residues 324–343).44
726 Investigation of the Properties of Fpn
61
Assuming that the N- and C-termini of Fpn are
cytosolic, as suggested by our data and some
previous studies,26,37,38 Fpn must have an even
number of TM spanning domains. Using the predic-
tion software TMHMM46 and an alignment of
human, mouse, and zebrafish Fpn sequences, we
predicted that Fpn contains 12 TM domains (Fig. 9),
differing from prior predictions of 9 or 10 membrane
spanning regions4,5,13 but similar to a recent predic-
tion published in conjunction with insertion muta-
genesis analyses.26 Our model places the tyrosines
that become phosphorylated upon hepcidin-25
binding, Y302 and Y303,11 in the middle of TM
region 6 (TM6) and thus not accessible to cytosolic
kinases. The model may be inaccurate in the region
of TM6, or, alternatively, the binding of hepcidin-
25 to the extracellular loop located between TM6
and TM7 could cause a conformational shift that
adjusts the location of TM6 such that Y302 and
Y303 become accessible to the cytosol where they
can be phosphorylated.
Although Fpn has been reported to be predomi-
nantly localized to the plasma membrane in the
absence of the peptide hormone hepcidin, previous
studies showed visible internal staining when Fpn
was stably or transiently expressed in HEK293T
cells.8,27–30,36 Here, we showed that much of the
internal Fpn-GFP signal was eliminated by treat-
ment with the protein synthesis inhibitor cyclohex-
imide when Fpn-GFP was transiently expressed in
HeLa cells (Fig. 5). Having worked out conditions
such that the majority of wild-type Fpn was
localized to the plasma membrane in the absence
of hepcidin, we were able to rapidly screen the
localization of disease-related Fpn mutants in the
presence and in the absence of hepcidin.
We found that wild-type Fpn-GFP and 16 of 16
disease-related Fpn-GFPmutants tested in this assay
localized primarily to the plasmamembrane of HeLa
cells (Fig. 5) upon treatment with cycloheximide in
the absence of hepcidin. These results conflict with
those of some studies conducted in the absence of
cycloheximide, with, for example, one report sug-
gesting that the A77D Fpn mutant is intracellular29
and others suggesting that the A77D,26 D157G,26
ΔV160,26,30,36 N174I,29 G323V,30,36 and G490D30 Fpn
mutants exhibited partial internalization. The dis-
crepancies may reflect cell type-specific differences
in folding rates; thus, slowly folding mutants might
appear to be intracellular in cells that were not
treated with cycloheximide. This is clearly not the
case for all cells, however, as we observed primarily
plasma membrane localization for wild-type Fpn-
GFP and the 16 disease-related mutants in polarized
MDCK cells, in which case the use of cycloheximide
to eliminate intracellular signals was not necessary
(Fig. 4).
Using the cycloheximide treatment procedure for
reproducibly expressing Fpn-GFP on the surface of
HeLa cells, we next investigated the responses of
Fpn mutants to hepcidin treatment. As previously
described,8 we found that wild-type Fpn-GFP was
internalized by the addition of hepcidin-25 to
HeLa cells (Fig. 5). In our experiments, we saw
internalization of the Fpn-GFP signal within 1 h of
incubation with 2.0 μM hepcidin-25, and by 4 h of
incubation, the Fpn-GFP signal in many cells was
entirely intracellular. Our experiments showed that
the internalized Fpn-GFP passes through EEA1-
and LAMP-positive compartments but does not
accumulate in the Golgi (Fig. 6) and that this
trafficking is dependent on intact microtubules
(Fig. 7).
There was some variability in the degree of wild-
type Fpn-GFP internalization in hepcidin-treated
cells, presumably due to different expression levels
in the transiently transfected cells; thus, we did not
attempt to quantify relative levels of Fpn internaliza-
tion for each of the mutants. Instead, we considered
an Fpn mutant to be hepcidin sensitive if we
observed distinct internal Fpn-GFP puncta after 4 h
of incubationwith 2 μMhepcidin-25 (a concentration
chosen to ensure saturation) and to be hepcidin
resistant if no distinct punctumwas observed. Using
these definitions, we report that the Fpn-GFP
mutants A77D, N144D, N144H, N144T, D157G,
ΔV160, N174I, Q182H, Q248H, D270V, and G323V
were hepcidin sensitive and that the Fpn-GFP
mutants Y64N, G80S, C326S, C326Y, and G490D
were hepcidin resistant (Fig. 5). The N144T, D270V,
and C326S Fpn mutants had not been tested for
hepcidin internalization prior to this report. Some of
the results for the othermutants conflict with those of
prior studies, whereas others are in agreement. For
example, one study reported N144H, D157G,
ΔV160, and G323V as hepcidin resistant yet agreed
with our results that G490D was resistant and that
Q182H was sensitive.30 Another study's results
differed from our results by reporting that the
A77D and N174I mutants were hepcidin resistant
and that the G80S mutant was hepcidin sensitive.29
A third study reported A77D, N144H, D157G,
ΔV160, Q182H, and G323V all as hepcidin re-
sistant.26 These discrepancies may have arisen from
different experimental conditions—the analyses
described in these studies were performed without
cycloheximide pretreatment and using a lower
hepcidin-25 concentration of 0.36 or 0.7 μM. How-
ever, an additional study that used cycloheximide
pretreatment and 0.5 μM hepcidin-25 agreed with
our results that Y64N and C326Y were hepcidin
resistant and that N144D, N144H, and Q248H were
at least partially internalized upon hepcidin treat-
ment.28 It should be noted that our analysis does not
distinguish between Fpn mutations within the
hepcidin-binding site that cause a reduced affinity
for hepcidin and mutations that prevent the Fpn–
hepcidin complex from interacting properly with
internalization machinery.
Linking the phenotypic manifestations of iron
overload in patients affected by ferroportin dis-
ease caused by specific mutations with in vitro
analyses on those same Fpn mutants has been
difficult. This is due to the heterogeneity of
patient phenotypes even between family members
sharing the same Fpn mutation, the lack of data
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for patients affected by certain mutations, and the
difficulty of working with Fpn in vitro (as
demonstrated by the conflicting experimental
results reported to date). However, by combining
our results with available clinical data, the data
presented in our study support a model in which
Fpn mutations resulting in hepcidin resistance in
vitro manifest themselves as a disease with high
transferrin saturation (observed in Y64N and
C326S),16,25 low to moderately high serum ferritin
levels (observed in Y64N and C326S),16,25 and
hepatocyte iron loading (observed in Y64N,
C326S, and G490D),16,20,25 whereas Fpn mutations
resulting in hepcidin sensitivity in vitro would
produce disease with low transferrin saturation
(observed in A77D, D157G, ΔV160, N174I,
Q182H, Q248H, and G323V),13–15,17,21,22,47–49 high
serum ferritin (observed in A77D, N144D, N144H,
N144T, D157G, ΔV160, N174I, Q182H, Q248H,
and G323V),13–15,17–19,21,22,47–50 and mostly macro-
phage/Kupffer cell iron loading with additional
hepatocyte iron loading in extreme cases (observed
in A77D, N144D, N144H, N144T, ΔV160, and
N174I).13,14,18,19,47–50
Materials and Methods
Insect cell expression of Fpn
Genes encoding human and mouse Fpn's were gifts of
Alain Townsend (Oxford), and the zebrafish Fpn gene was
the gift of Nancy Andrews (Duke University School of
Medicine). Human, mouse, and zebrafish Fpn's were
expressed in a lytic baculovirus/insect cell expression
system. A Rho tag was added to each construct using PCR
by replacing the Fpn start codon with the first 20 aa of
bovine rhodopsin and a linker (nucleic acid sequence,
ATGAACGGGACCGAGGGCCCAAACTTCTACGTGCC-
TTTCTCCAACAAGACGGGCGTGGTAGGCCGGCCGC-
GGCCGCGA). The C-termini of the insect cell constructs
were tagged with 10×-Histidine (Rho-Fpn-His) or tandem
10×-Histidine and FLAG (Rho-Fpn-His-FLAG) tags and a
linker (nucleic acid sequence, AGCGGCCGC-
GAAAACTTGTACTTTCAAGGCCATCACCATCACCAT-
CACCATCACCATCACGACTACAAGGACGACGACGA-
CAAGGGCGCGCCT). Constructs were subcloned into
pBacPAK8 (Clontech), and viruses were constructed using
ProGreen Baculovirus DNA (AB Vector). GFP expression
was used to titrate the virus required to attain N95%
infection. For protein expression, 5 L ofHighFive insect cells
in ESF 921 medium (Expression Systems) was grown using
a 20/50EH Wave Bioreactor (GE Healthcare) (settings:
rocking speed, 9; angle, 20°; temperature, 27 °C; and
ambient air pumped in at 0.3 L/min). Cells were infected
at a density of 2.5–3.5×106 viable cells/mL and were
harvested 48 h after infection.
Solubilization of Fpn from membranes
All steps were performed on ice or at 4 °C. Cell paste
(110–140 g) was resuspended in 900 mL of resuspension
buffer [50 mM Tris, pH 7.5, 150 mM NaCl, and 18
ethylenediaminetetraacetic acid (EDTA)-free complete
protease inhibitor tablets (Roche)]. Cells were disrupted
by sonication in 50-mL fractions on ice and placed in an ice
bath between sonication rounds. Cell debris and mem-
branes were pelleted at 125,000g.
Membrane pellets were resuspended using a Dounce
homogenizer in 300 mL of detergent-free solubilization
buffer [50 mM Tris, pH 7.5, 500 mM NaCl, 10 mM
imidazole, pH 7.5, and six EDTA-free complete protease
inhibitor tablets (Roche)]. Dry DM (Anatrace) or DDM
(Anatrace) was added to 1% (w/v) to resuspended
membranes and incubated with gentle stirring at 4 °C
for 2.5 h. After pelleting at 125,000g, membrane suspen-
sions were filtered at 0.45 μm.
Affinity purification of Fpn
Detergent-solubilized Fpn was purified by single (Rho-
Fpn-His) or double (Rho-Fpn-His-FLAG) affinity steps.
For His-tag purifications, TALON SuperFlow columns
were preequilibrated with solubilization buffer containing
0.02% (w/v) DDM. Supernatants were passed over the
column and washed to baseline. Nonspecific binders were
washed off with equilibration buffer containing 30 mM
imidazole, and Fpn was eluted with buffer containing
120 mM imidazole.
Rho-Fpn-His-FLAG was further purified using an anti-
FLAGM2 affinity column (Sigma) equilibrated in TALON
elution buffer. TALON eluates were passed over the
affinity column twice, which was washed with M2 buffer
[50 mM Tris, pH 7.5, 150 mM NaCl, and 0.02% (w/v)
DDM] and eluted with M2 buffer containing 0.2 mg/mL
of FLAG peptide (Sigma). Boiling of samples in SDS
sample buffer resulted in aberrant migration near the top
of an SDS-PAGE gel, so gel samples were not boiled prior
to loading.
Molecular mass and oligomeric state determination
by SEC-LS/UV/RI
SEC was conducted with in-line multiangle static LS to
determine the molecular mass of purified Fpn. The FLAG
column eluate was concentrated to 0.5 mL using a 50-kDa
cutoff Amicon Ultra concentrator (Millipore) and passed
over a Superdex 200 10/300 SEC column (GE Healthcare)
preequilibrated in buffer containing 50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, and 0.02% (w/v) DDM at 0.5 mL/
min. The SEC column was plumbed in-line with a
multiangle static LS monitor at 658 nm (DAWN Helios,
Wyatt), a differential RI monitor (Optilab rEX, Wyatt), and
a UV absorbance monitor (AKTA Explorer, GE Health-
care). All calculations of molecular mass were performed
using the protein conjugate template in the ASTRA 5.3.2
software package (Wyatt). The specific RI increment (dn/
dc) values used were 0.185 for protein (Wyatt) and 0.133
for DDM.51 The predicted molecular mass and extinction
coefficient for UV absorbance at 280 nm for Rho-Fpn-His-
FLAG were calculated from the amino acid sequence as
69,015 g/mol and 83,319 M−1 cm−1, respectively.52 Bovine
serum albumin (GE Healthcare) was used as a calibration
standard.
Fpn–hepcidin binding
Experiments evaluating the interaction between human
Fpn and human hepcidin were performed at 25 °C using a
Biacore 2000 Instrument (GE Healthcare). Interactions
between immobilized Fpn on a sensor chip and hepcidin
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injected over the sensor surface were monitored in real
time as resonance units (RUs). An anti-Rho monoclonal
antibody (see below) was immobilized at densities
ranging from 1000 to 3000 RUs to the surface of a CM5
biosensor chip using primary amine chemistry as
described in the Biacore manual. Purified Rho-Fpn-His
in 50 mM Tris, pH 7.5, 150 mMNaCl, and 0.2% (w/v) DM
was injected over the anti-Rho surface, capturing 1000–
1500 RUs of Fpn. Flow cells containing immobilized anti-
Rho antibody without captured Rho-Fpn-His were used
as reference-subtracted negative controls. The sensor
surface was monitored for N12 h in the same buffer until
a stable baseline was reached. Hepcidin-25 (Bachem) or
hepcidin-20 (gift of Prof. T. Ganz, UCLA) diluted in this
buffer was injected over the Fpn surface at various
concentrations. The surface was observed to return to
baseline after 1 h, so no regeneration condition was
required. Experiments directly comparing the binding of
hepcidin-20 and that of hepcidin-25 to immobilized Fpn
were performed using 10 μM hepcidin injections. For
experiments to derive kinetic constants for the hepcidin-
25–Fpn interaction, a dilution series (0.625, 1.25, 2.5, 5.0,
8.0, and 10 μM) of hepcidin-25 were injected, and the
dissociation and association phases of all curves were
simultaneously fit to derive kinetic constants using
BIAevaluation 4.1 (GE Healthcare). The data did not fit
well to a 1:1 bindingmodel, which can result if the injected
analyte is not homogeneous (e.g., the analyte contains a
population of aggregates).53 An approximate equilibrium
dissociation constant (Kd) was calculated from the ratio of
dissociation and association rate constants.
Construction and mutagenesis of mammalian
expression constructs
Fpn-GFP and Rho-Fpn-GFP mammalian expression
vectors were constructed in the pLox+CMV expression
vector, containing the CMV promoter and SV40 polyA
tail. PCR inserts containing the Fpn-GFP or Rho-Fpn-GFP
were produced by bridging PCR using the Fpn gene and
the GFP gene derived from pCGFP-EU.39 Fpn-GFP
mutants were produced using site-directed mutagenesis.
All constructs were verified by sequencing.
Mammalian cell culture and transfections
HEK293T, HeLa, and MDCK cells were grown in
Dulbecco's modified Eagle's medium containing 4.5 g/L
of D-glucose, 4 mM L-glutamine, 110 mg/L of sodium
pyruvate (Gibco) with 1× penicillin/streptomycin (Gibco),
and 10% (v/v) fetal bovine serum (Atlanta Biologicals).
All transfections were performed using Lipofectamine
2000 (Invitrogen) as per the manufacturer's instruction.
MDCK cells grown on transwell filters were initially
seeded into six-well plates and transfected at ∼75%
confluency. Twenty-four hours later, cells were treated
with trypsin-EDTA and 5×105 cells were transferred to 12-
mm polyester transwell permeable supports (Costar) with
0.5 mL of growth medium above and 1.0 mL of growth
medium below the support. Transfected cells were grown
for 4 days postconfluency before imaging to ensure full
polarization and tight junction formation.
FSEC analysis
Wild-type and mutant human Fpn-GFP constructs were
transiently expressed inHEK293Tcells in a six-well format.
Cells were collected by pipetting 36–40 h post-transfection
and then pelleted and resuspended in 500 μL of solubiliza-
tion buffer [50mMTris, pH 7.5, 150mMNaCl, and 1% (w/
v) DDM]. Resuspended cells were lysed by sonication, and
solubilization was performed with gentle agitation for
2.5 h at 4 °C. Unsolubilized material was pelleted at
125,000g. The supernatant was removed and filtered
through a 0.22-μm Ultrafree-MC spin filter (Millipore).
Filtered supernatant was loaded onto a Superdex 200 10/
300 SEC column (GE Healthcare) and Fpn-GFP fluores-
cence was monitored using an online RF-10AXL fluores-
cence detector (488-nm excitation, 507-nm emission;
Shimadzu). SEC was performed at 0.5 mL/min in 50 mM
Tris, pH 7.5, 150 mM NaCl, and 0.2% (w/v) DDM.
Hepcidin-induced Fpn internalization
HeLa cells were seeded onto polylysine-coated glass
coverslips at 106 cells/well in a six-well format, and Fpn-
GFP constructs were transfected at ∼80% confluency.
After 20 h, cells were incubated in medium containing
75 μg/mL of cycloheximide (Sigma) for 2 h. This medium
was then exchanged for medium containing 2.0 μM
hepcidin-25 (Bachem) and 75 μg/mL of cycloheximide.
Each internalization time point included a negative
control in which cells were treated only with cyclohex-
imide. Internalization was stopped by fixing cells at room
temperature (∼22 °C) for 15 min with 4% (v/v)
paraformaldehyde in phosphate-buffered saline (PBS)
containing 1 mM CaCl2, 0.5 mM MgCl2, and 0.25 mM
MgSO4. Fixed samples were washed twice and directly
mounted on glass slides in ProLong GOLD Anti-Fade
mounting medium containing DAPI (4′,6-diamidino-2-
phenylindole) nuclear stain (Invitrogen) or quenched in
PBS containing 75 mM NH4Cl and 20 mM glycine for
10 min prior to blocking and further antibody treatments.
After quenching, samples were incubated in blocking
solution [PBS containing 8% (v/v) goat serum (Gibco) and
0.025% (w/v) saponin (Sigma)] for 30 min at room
temperature. Primary antibody incubations were per-
formed in blocking solution overnight at 4 °C. After
primary incubation, cells were washed three times in PBS
and then incubated in blocking solution containing
secondary antibodies for 1 h at room temperature, fixed
in PBS containing 4% (v/v) paraformaldehyde for 30 min,
washed twice in PBS, and then mounted on glass slides as
described above.
Antibodies
Amousemonoclonal anti-Rho tag antibody (hybridoma
B630N) was purified from ascites fluid using a protein G
affinity column followed by SEC. Other antibodies were
purchased or received as gifts as indicated. Primary
antibodies and the dilutions used for cell staining were
the monoclonal mouse anti-Rho at 1 μg/mL, Alexa-647-
conjugated rabbit polyclonal anti-GFP (Invitrogen, cat. no.
A31852) at 1:500, AC17 mouse monoclonal anti-LAMP2
from E. Rodriguez-Boulan (Cornell University) at 1:1000,
rabbit polyclonal anti-LAMP1 (Abcam, cat. no. ab24170) at
1:500, rabbit polyclonal anti-EEA1 (Santa Cruz Biotech, cat.
no. SC-33585) at 1:100, and mouse monoclonal anti-Golgi
58-kDa protein (Abcam, cat. no. ab6284) at 1:100. Second-
ary antibodies and their dilutions were Alexa-647-con-
jugated goat anti-mouse immunoglobulin G (Invitrogen,
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cat. no. A21235) at 1:500 and Alexa-647-conjugated F(ab′)2
fragment of goat anti-rabbit immunoglobulin G (Invitro-
gen, cat. no. A21246) at 1:500.
Confocal imaging and image processing
Confocal images were recorded on an UltraVIEW ERS
Rapid Confocal Imager (Perkin-Elmer) using 63×(Plan-
APOCHROMAT 1.4 Oil DIC, Zeiss) or 100×( αPlan-
APOCHROMAT 1.46 Oil DIC, Zeiss) objectives. GFP and
Alexa-647 fluorophores were excited at 488 and 647 nm,
respectively, using a 488/548/647 multiline argon/kryp-
ton laser (Melles Griot). All fixed cells that were imaged
had intact nuclei, as determined by DAPI staining (data
not shown). Confocal images shown from fixed samples
are representative images from full 3D confocal stacks
sampled at 0.25-μm spacing in z. Stacks of imaged HeLa,
HEK293T, and MDCK cells were assembled, and thresh-
olds were set in Imaris 6.0.1 (Bitplane) before single
representative slices were exported and assembled into
figures using Photoshop CS3 (Adobe).
Live imaging and tracking
HeLa cells were grown and transfected in 35-mm
polylysine-coated glass-bottomed microwell dishes
(Matek). Two dishes were seeded at a density of
106 cells/dish and transfected at ∼80% confluency on the
following day with Fpn-GFP. After 20 h, the medium was
exchanged for medium containing 75 μg/mL of cyclohex-
imide lacking phenol red. After 2 h, the medium was
exchanged for phenol red-free medium containing 2 μM
hepcidin-25 and 75 μg/mLof cycloheximide. After another
2 h, dishes were chilled on ice and their medium was
exchanged for phenol red-free medium containing 10 μg/
mL of nocodazole, 2 μM hepcidin-25, and 75 μg/mL of
cycloheximide or the same chilled medium lacking
nocodazole. Samples were incubated for 30 min on ice
and then moved to an UltraVIEW ERS Rapid Confocal
Imager (Perkin-Elmer) with a temperature-controlled
housing (Solent Scientific) where they were warmed to
37 °C for imaging. Fluorescent micrographs were collected
at 100×( αPlan-APOCHROMAT 1.46 Oil DIC, Zeiss) in a
single focal plane 1 μm above the glass support and
imaged at 4.5 frames per second for 90 s per cell. Three cells
from each condition were imaged. Fpn-GFP-containing
compartments were tracked using the tracking module in
Imaris 6.0.1 (Bitplane). Spots and tracks were automati-
cally selected using Imaris parameters, estimated
diameter=0.35 μm, threshold=8, Brownian motion track-
ing algorithm, maximum distance=0.66 μm, and gap
size=3, with minimal manual removal required. Tracks
shorter than 10 frames (2.2 s) were filtered out of the data
set. The final data set includes 1295 tracks for the untreated
sample and 1149 tracks for the nocodazole-treated sample.
Transmembrane topology prediction
DNA sequences for full-length human, mouse, and
zebrafish Fpn's were submitted to TransMembrane
Prediction using the Hidden Markov Model (TMHMM
v2.0) prediction server.46 Each sequence was predicted
to contain 12 regions that were 21–23 aa in length with
a significant (N60%) probability of being a TM region.
TMHMM marked 10 of these regions as TMs in human
and mouse Fpn's, and 8 in zebrafish Fpn, which upon
alignment summed to a total of 11 TMs. A final region
with much of its sequence at or above 60% probability
of being a TM was not annotated as a TM in any of the
three Fpn sequences, but we included it in our model
for a final prediction of 12 TMs (Fig. 9). The
approximate starting and ending points for the pre-
dicted TMs (using the residue numbering for human
Fpn) are as follows: 12–34, 58–80, 93–115, 125–147, 175–
195, 199–221, 293–315, 335–357, 373–395, 450–472, 492–
514, and 519–541.
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Chapter 3:
Expression, Detergent Extraction, and Purification of 
Recombinant Human, Mouse, and Zebrafish Ferroportin 
from Bacteria and Baculovirus-Infected Insect Cells
In this chapter we report the over-expression, detergent extraction, purification, and 
preliminary analysis of recombinant ferroportin from various vertebrate species.    
68
Introduction
This chapter focuses on the over-expression, detergent-extraction and purification of 
human, mouse, and zebrafish forms of ferroportin (Fpn) for use in various biophysical 
analyses and crystallization attempts.  Prior to our studies, recombinant Fpn expression 
had been limited to small-scale eukaryotic systems.  For example, the initial studies in 
which Fpn was identified and partially characterized involved small-scale recombinant 
expression Fpn utilizing such methods as microinjection in Xenopus oocytes (Donovan et 
al. 2000; McKie et al. 2000) or zebrafish embryos (Donovan et al. 2000), or by transient 
transfection in mammalian tissue culture lines, such as Madin-Darby canine kidney cells 
(MDCK) (McKie et al. 2000), CaCo-2 cells (McKie et al. 2000), or HEK293T cells 
(Abboud and Haile 2000). Fpn expression in these systems was evaluated by sensitive 
detection techniques such as Western blotting, direct  fluorescence (in the case of Fpn-
GFP), or immunofluorescence.  Subsequent Fpn studies used these same small-scale 
eukaryotic expression methods (De Domenico et al. 2005, 2006, 2007a,b,c; Drakesmith 
et al. 2005; Goncalves et al. 2006; Nemeth et al. 2004; Schimanski et al. 2005; 2008), 
and no attempts at Fpn over-expression or purification beyond those reported in chapter 2 
(Rice et al. 2009) have been reported to date. 
Our Fpn over-expression strategy involved both prokaryotic and eukaryotic methods. 
Prokaryotic expression tests were performed in various strains of the bacterium E. coli 
and eukaryotic expression tests were performed using baculoviruses to infect High Five 
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and Sf9 insect cell lines. Initial efforts in both prokaryotic and eukaryotic systems yielded 
no Fpn expression (as assessed by Western blotting), however after extensive testing of 
various Fpn constructs under a large number of expression conditions we were able to 
successfully  over-express human, mouse, and zebrafish Fpns at adequate levels for 
biophysical characterization and crystallization trials as will be described in this chapter.
Once an over-expression protocol was worked out, detergent-extraction protocols were 
developed for the solubilization of Fpn from prokaryotic and eukaryotic membranes.  We 
found that Fpns expressed in insect cell plasma membranes were much more amenable to 
detergent extraction than Fpns expressed in the inner membrane of E. coli.  The 
detergents that were capable of extracting Fpn were then used to develop purification 
protocols.  The eukaryotic expression and purification was reported in Chapter 2 (Rice et 
al. 2009), but due to word limits in the published format, certain details were left out or 
not covered in full.  These details will be discussed in more detail in this chapter.   The 
first section of this chapter reports the expression, extraction, and purification for the 
expression of Fpn in bacteria, and the second portion is devoted to similar studies in 
insect cells.  
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Materials and Methods
Bacterial Expression Constructs
Human and mouse Fpn genes were gifts from Professor Alain Townsend (Oxford, UK) 
and zebrafish Fpn gene was a gift from Professor Nancy Andrews (Duke University). The 
human gene was contained within a mammalian expression construct, with the name 
hfpn1-V571A-myc-His6-pcDNA3.1. It contained an accidentally  introduced V571A 
mutation. This mutation was reversed by site-directed mutagenesis, before sub-cloning of 
this gene continued. The mouse gene was contained within a mammalian expression 
construct, with the name mfpn1-myc-His6-pcDNA3.1. The zebrafish gene was contained 
within a mammalian expression construct  with the name zfpn1-GFP-pEGFP-N1. The 
human and zebrafish genes naturally contained an NdeI restriction enzyme sequence 
within their ORFs, and these were removed by mutagenesis prior to further mutagenesis 
and/or sub-cloning into bacterial expression vectors.  Our cloning strategy for bacterial 
expression constructs was to work with three separate forms of each Fpn: wild-type; 
A77D; and N144H. The A77D and N144H mutants have been identified as disease-
causing Fpn mutations (Montosi et al. 2001; Njajou et al. 2001), however, how these 
mutations lead to disease was unknown.  We surmised that these mutants were worth 
pursuing alongside the wild-type Fpn for initial expression studies, particularly if 
expression of the fully functional wild-type Fpn was toxic due to unregulated iron export 
from cells.  Each Fpn form was then directionally  subcloned into the NdeI and NotI sites 
of pET-23a (Novagen) for a C-terminal 6× His tag, pET-28b (Novagen) for an N-terminal 
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6× His tag, pMAL-p2E (New England Biolabs) for an N-terminal maltose binding 
protein fusion, or alternately into pET-28b adding His and/or StrepTagII tags via PCR. 
Gene expression in these vectors was driven by  the T7 promoter in pET vectors and by 
Ptac promoter in the pMAL vector, both of which were induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG) addition.  Sequencing the constructs revealed an unplanned 
result for two forms of human Fpn in pET-28b (wild-type and N144H), in which the final 
constructs had both N- and C-terminal His tags.  These constructs (pAER113a and 
pAER115a) with affinity tags on both termini were included in the expression screening. 
The bacterial expression constructs are summarized in table 3.1.
Table 3.1. Bacterial expression constructs
Plasmid Name Gene or Insert Name Parent Vector N-terminal tag C-terminal tag
pAER112 human Fpn (w.t.) pET-23a none His6
pAER113a human Fpn (w.t.) pET-28b His6 His6
pAER114 human Fpn N144H pET-23a none His6
pAER115a human Fpn N144H pET-28b His6 myc-His6
pAER116 human Fpn A77D pET-23a none His6
pAER117 human Fpn A77D pET-28b His6 none
pAER118 mouse Fpn (w.t.) pET-23a none His6
pAER119 mouse Fpn (w.t.) pET-28b His6 none
pAER120 mouse Fpn N144H pET-23a none His6
pAER121 mouse Fpn N144H pET-28b His6 none
pAER122 mouse Fpn A77D pET-23a none His6
pAER123 mouse Fpn A77D pET-28b His6 none
pAER124 zebrafish Fpn (w.t.) pET-23a none His6
pAER125 zebrafish Fpn (w.t.) pET-28b His6 none
pAER126 zebrafish Fpn N144H pET-23a none His6
pAER128 zebrafish Fpn A77D pET-23a none His6
pAER136 mouse Fpn (w.t.) pMAL-p2E MBP His6
pDZS110 human Fpn (w.t.) pET-28b His6 Strep
pET-HS-1c human Fpn (w.t.) pET-28b His6-Strep none
pET-HS-3a human Fpn (w.t.) pET-28b His6-Strep His6
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Small-Scale Tests of Fpn Expression in E. coli
Expression constructs were tested for Fpn expression in over 900 expression conditions, 
exploring variables such as: E. coli strain; induction temperature; growth media 
formulation; induction length; concentration of inducer; and aeration levels. Media 
formulations are summarized in table 3.2 and expression tests are summarized in table 
3.3. Overnight cultures in the media of choice were grown from glycerol stocks at 37 ºC 
shaking at 240 rpm.  The following morning, 5 mL cultures in 50 mL plastic conical vials 
(Falcon) with their caps loosely  taped in place to allow adequate aeration were inoculated 
with 100 µL of overnight culture and incubated at 37 ºC and 240 rpm.  The optical 
density, as measured at 600 nm (OD600), of the growth culture was monitored routinely. 
When cultures reached an OD600 between 0.5 and 1.0, cultures were moved to an 
incubator at a preset temperature agitating at 240 rpm, a 1 mL fraction was removed as 
the zero time point, and the remaining 4 mL were induced by  addition of IPTG to a final 
concentration of 0.4 mM IPTG.  Induced cultures were allowed to incubate for various 
times before 1 mL fractions were removed for analysis.  Cells from fractions removed for 
analysis were spun down for 1 min at 13,000×g, after which the supernatant was 
aspirated and the cell pellet frozen at −20 ºC until Western blot analysis could be 
performed, as described below.  Using this technique, a single 5 mL culture would be 
used to test up to 4 time points for a given condition.  The expression tests summarized in 
table 3.3 that report >4 time points were performed in larger volumes but otherwise 
adhered to the protocol described here.
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Table 3.2. Growth media formulations
LB 2×YT SOC TB TB1 TB2 TB3 TB4 TB5 TB6 TB7
bactotryptone  
(g/L) 10 16 20 12 12 12 12 12 12 12 12
yeast extract    
(g/L) 5 10 5 24 24 12 - 8 12 - -
malt extract (g/L) - - - - - - - 8 12 24 12
beef extract (g/L) - - - - - 12 24 8 - - 12
NaCl (g/L) 10 5 0.58 - - - - - - - -
KCl (g/L) - - 0.18 - - - - - - - -
MgCl2•6H20 (g/L) - - 2.03 - - - - - - - -
MgSO4 (g/L) - - 1.20 - - - - - - - -
1M glucose   
(mL/L) - - 20 - - - - - - - -
gycerol (mL/L) - - - 4 8 8 8 8 8 8 8
KH2PO4 (g/L) - - - 2.31 2.31 2.31 2.31 2.31 2.31 2.31 2.31
K2HPO4 (g/L) - - - 12.54 12.54 12.54 12.54 12.54 12.54 12.54 12.54
Table 3.3. Bacterial expression test summary
Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER112 BL21(DE3) 37 TB - 1, 5 no
pAER114 BL21(DE3) 37 TB - 1, 5 no
pAER116 BL21(DE3) 37 TB - 1, 5 no
pAER118 BL21(DE3) 37 TB - 1, 5 no
pAER120 BL21(DE3) 37 TB - 1, 5 no
pAER122 BL21(DE3) 37 TB - 1, 5 no
pAER124 BL21(DE3) 37 TB - 1, 5 no
pAER113a BL21(DE3) 37 TB - 1, 5 yes
pAER115a BL21(DE3) 37 TB - 1, 5 yes
pAER117 BL21(DE3) 37 TB - 1, 5 no
pAER119 BL21(DE3) 37 TB - 1, 5 no
pAER121 BL21(DE3) 37 TB - 1, 5 no
pAER123 BL21(DE3) 37 TB - 1, 5 no
pAER125 BL21(DE3) 37 TB - 1, 5 no
pAER112 BL21(DE3) 30 TB - 3, 8 no
pAER114 BL21(DE3) 30 TB - 3, 8 no
pAER116 BL21(DE3) 30 TB - 3, 8 no
pAER118 BL21(DE3) 30 TB - 3, 8 no
pAER120 BL21(DE3) 30 TB - 3, 8 no
pAER122 BL21(DE3) 30 TB - 3, 8 no
pAER124 BL21(DE3) 30 TB - 3, 8 no
pAER113a BL21(DE3) 30 TB - 3, 8 no
pAER115a BL21(DE3) 30 TB - 3, 8 yes
pAER117 BL21(DE3) 30 TB - 3, 8 no
pAER119 BL21(DE3) 30 TB - 3, 8 no
pAER121 BL21(DE3) 30 TB - 3, 8 no
pAER123 BL21(DE3) 30 TB - 3, 8 no
pAER125 BL21(DE3) 30 TB - 3, 8 no
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER112 BL21(DE3) 37 LB - 1, 5 no
pAER114 BL21(DE3) 37 LB - 1, 5 no
pAER116 BL21(DE3) 37 LB - 1, 5 no
pAER118 BL21(DE3) 37 LB - 1, 5 no
pAER120 BL21(DE3) 37 LB - 1, 5 no
pAER122 BL21(DE3) 37 LB - 1, 5 no
pAER124 BL21(DE3) 37 LB - 1, 5 no
pAER113a BL21(DE3) 37 LB - 1, 5 no
pAER115a BL21(DE3) 37 LB - 1, 5 no
pAER117 BL21(DE3) 37 LB - 1, 5 no
pAER119 BL21(DE3) 37 LB - 1, 5 no
pAER121 BL21(DE3) 37 LB - 1, 5 no
pAER123 BL21(DE3) 37 LB - 1, 5 no
pAER125 BL21(DE3) 37 LB - 1, 5 no
pAER112 BL21(DE3) 30 LB - 3, 8 no
pAER114 BL21(DE3) 30 LB - 3, 8 no
pAER116 BL21(DE3) 30 LB - 3, 8 no
pAER118 BL21(DE3) 30 LB - 3, 8 no
pAER120 BL21(DE3) 30 LB - 3, 8 no
pAER122 BL21(DE3) 30 LB - 3, 8 no
pAER124 BL21(DE3) 30 LB - 3, 8 no
pAER113a BL21(DE3) 30 LB - 3, 8 no
pAER115a BL21(DE3) 30 LB - 3, 8 no
pAER117 BL21(DE3) 30 LB - 3, 8 no
pAER119 BL21(DE3) 30 LB - 3, 8 no
pAER121 BL21(DE3) 30 LB - 3, 8 no
pAER123 BL21(DE3) 30 LB - 3, 8 no
pAER125 BL21(DE3) 30 LB - 3, 8 no
pAER112 BL21(DE3) 37 SOC - 1, 5 no
pAER114 BL21(DE3) 37 SOC - 1, 5 no
pAER116 BL21(DE3) 37 SOC - 1, 5 no
pAER118 BL21(DE3) 37 SOC - 1, 5 no
pAER120 BL21(DE3) 37 SOC - 1, 5 no
pAER122 BL21(DE3) 37 SOC - 1, 5 no
pAER124 BL21(DE3) 37 SOC - 1, 5 no
pAER113a BL21(DE3) 37 SOC - 1, 5 no
pAER115a BL21(DE3) 37 SOC - 1, 5 no
pAER117 BL21(DE3) 37 SOC - 1, 5 no
pAER119 BL21(DE3) 37 SOC - 1, 5 no
pAER121 BL21(DE3) 37 SOC - 1, 5 no
pAER123 BL21(DE3) 37 SOC - 1, 5 no
pAER125 BL21(DE3) 37 SOC - 1, 5 no
pAER112 BL21(DE3) 30 SOC - 3, 8 no
pAER114 BL21(DE3) 30 SOC - 3, 8 no
pAER116 BL21(DE3) 30 SOC - 3, 8 no
pAER118 BL21(DE3) 30 SOC - 3, 8 no
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER120 BL21(DE3) 30 SOC - 3, 8 no
pAER122 BL21(DE3) 30 SOC - 3, 8 no
pAER124 BL21(DE3) 30 SOC - 3, 8 no
pAER113a BL21(DE3) 30 SOC - 3, 8 no
pAER115a BL21(DE3) 30 SOC - 3, 8 no
pAER117 BL21(DE3) 30 SOC - 3, 8 no
pAER119 BL21(DE3) 30 SOC - 3, 8 no
pAER121 BL21(DE3) 30 SOC - 3, 8 no
pAER123 BL21(DE3) 30 SOC - 3, 8 no
pAER125 BL21(DE3) 30 SOC - 3, 8 no
pAER112 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER114 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER116 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER118 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER120 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER122 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER124 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER113a RosettaBlue(DE3) 37 TB - 1, 5 no
pAER115a RosettaBlue(DE3) 37 TB - 1, 5 no
pAER117 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER119 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER121 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER123 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER125 RosettaBlue(DE3) 37 TB - 1, 5 no
pAER112 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER114 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER116 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER118 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER120 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER122 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER124 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER113a RosettaBlue(DE3) 23 TB - 4, 8 no
pAER115a RosettaBlue(DE3) 23 TB - 4, 8 no
pAER117 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER119 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER121 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER123 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER125 RosettaBlue(DE3) 23 TB - 4, 8 no
pAER112 BL21(DE3) 37 2×YT - 1, 5 no
pAER114 BL21(DE3) 37 2×YT - 1, 5 no
pAER116 BL21(DE3) 37 2×YT - 1, 5 no
pAER118 BL21(DE3) 37 2×YT - 1, 5 no
pAER120 BL21(DE3) 37 2×YT - 1, 5 no
pAER122 BL21(DE3) 37 2×YT - 1, 5 no
pAER124 BL21(DE3) 37 2×YT - 1, 5 no
pAER113a BL21(DE3) 37 2×YT - 1, 5 no
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER115a BL21(DE3) 37 2×YT - 1, 5 no
pAER117 BL21(DE3) 37 2×YT - 1, 5 no
pAER119 BL21(DE3) 37 2×YT - 1, 5 no
pAER121 BL21(DE3) 37 2×YT - 1, 5 no
pAER123 BL21(DE3) 37 2×YT - 1, 5 no
pAER125 BL21(DE3) 37 2×YT - 1, 5 no
pAER112 BL21(DE3) 23 2×YT - 4, 8 no
pAER114 BL21(DE3) 23 2×YT - 4, 8 no
pAER116 BL21(DE3) 23 2×YT - 4, 8 no
pAER118 BL21(DE3) 23 2×YT - 4, 8 no
pAER120 BL21(DE3) 23 2×YT - 4, 8 no
pAER122 BL21(DE3) 23 2×YT - 4, 8 no
pAER124 BL21(DE3) 23 2×YT - 4, 8 no
pAER113a BL21(DE3) 23 2×YT - 4, 8 no
pAER115a BL21(DE3) 23 2×YT - 4, 8 no
pAER117 BL21(DE3) 23 2×YT - 4, 8 no
pAER119 BL21(DE3) 23 2×YT - 4, 8 no
pAER121 BL21(DE3) 23 2×YT - 4, 8 no
pAER123 BL21(DE3) 23 2×YT - 4, 8 no
pAER125 BL21(DE3) 23 2×YT - 4, 8 no
pAER112 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER114 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER116 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER118 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER120 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER122 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER124 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER113a RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER115a RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER117 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER119 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER121 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER123 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER125 RosettaBlue(DE3) 37 2×YT - 1, 5 no
pAER112 RosettaBlue(DE3) 23 2×YT - 10 no
pAER114 RosettaBlue(DE3) 23 2×YT - 10 no
pAER116 RosettaBlue(DE3) 23 2×YT - 10 no
pAER118 RosettaBlue(DE3) 23 2×YT - 10 no
pAER120 RosettaBlue(DE3) 23 2×YT - 10 no
pAER122 RosettaBlue(DE3) 23 2×YT - 10 no
pAER124 RosettaBlue(DE3) 23 2×YT - 10 no
pAER113a RosettaBlue(DE3) 23 2×YT - 10 no
pAER115a RosettaBlue(DE3) 23 2×YT - 10 no
pAER117 RosettaBlue(DE3) 23 2×YT - 10 no
pAER119 RosettaBlue(DE3) 23 2×YT - 10 no
pAER121 RosettaBlue(DE3) 23 2×YT - 10 no
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER123 RosettaBlue(DE3) 23 2×YT - 10 no
pAER125 RosettaBlue(DE3) 23 2×YT - 10 no
pAER112 Rosetta(DE3) 37 TB - 1, 5 no
pAER114 Rosetta(DE3) 37 TB - 1, 5 no
pAER116 Rosetta(DE3) 37 TB - 1, 5 no
pAER118 Rosetta(DE3) 37 TB - 1, 5 no
pAER120 Rosetta(DE3) 37 TB - 1, 5 no
pAER122 Rosetta(DE3) 37 TB - 1, 5 no
pAER124 Rosetta(DE3) 37 TB - 1, 5 no
pAER113a Rosetta(DE3) 37 TB - 1, 5 no
pAER115a Rosetta(DE3) 37 TB - 1, 5 no
pAER117 Rosetta(DE3) 37 TB - 1, 5 no
pAER119 Rosetta(DE3) 37 TB - 1, 5 no
pAER121 Rosetta(DE3) 37 TB - 1, 5 no
pAER123 Rosetta(DE3) 37 TB - 1, 5 no
pAER125 Rosetta(DE3) 37 TB - 1, 5 no
pAER112 Rosetta(DE3) 30 TB - 3, 8 no
pAER114 Rosetta(DE3) 30 TB - 3, 8 no
pAER116 Rosetta(DE3) 30 TB - 3, 8 no
pAER118 Rosetta(DE3) 30 TB - 3, 8 no
pAER120 Rosetta(DE3) 30 TB - 3, 8 no
pAER122 Rosetta(DE3) 30 TB - 3, 8 no
pAER124 Rosetta(DE3) 30 TB - 3, 8 no
pAER113a Rosetta(DE3) 30 TB - 3, 8 no
pAER115a Rosetta(DE3) 30 TB - 3, 8 no
pAER117 Rosetta(DE3) 30 TB - 3, 8 no
pAER119 Rosetta(DE3) 30 TB - 3, 8 no
pAER121 Rosetta(DE3) 30 TB - 3, 8 no
pAER123 Rosetta(DE3) 30 TB - 3, 8 no
pAER125 Rosetta(DE3) 30 TB - 3, 8 no
pAER136 BL21(DE3) 37 TB - 1, 5 no
pAER136 BL21(DE3) 30 TB - 3, 8 no
pAER136 BL21(DE3) 37 2×YT - 1, 5 no
pAER136 BL21(DE3) 30 2×YT - 3, 8 no
pAER118 BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 no
pAER124 BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 no
pAER118 BL21(DE3) 37 TB2 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 37 TB2 - 0.5, 1, 2.5, 5 no
pAER124 BL21(DE3) 37 TB2 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 37 TB2 - 0.5, 1, 2.5, 5 no
pAER118 BL21(DE3) 30 TB1 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 30 TB1 - 0.75, 1.5, 4, 8 no
pAER124 BL21(DE3) 30 TB1 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 30 TB1 - 0.75, 1.5, 4, 8 no
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER118 BL21(DE3) 30 TB2 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 30 TB2 - 0.75, 1.5, 4, 8 no
pAER124 BL21(DE3) 30 TB2 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 30 TB2 - 0.75, 1.5, 4, 8 no
pAER118 BL21(DE3) 23 TB1 - 1, 3, 8, 16 no
pAER119 BL21(DE3) 23 TB1 - 1, 3, 8, 16 no
pAER124 BL21(DE3) 23 TB1 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 23 TB1 - 1, 3, 8, 16 no
pAER118 BL21(DE3) 23 TB2 - 1, 3, 8, 16 no
pAER119 BL21(DE3) 23 TB2 - 1, 3, 8, 16 no
pAER124 BL21(DE3) 23 TB2 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 23 TB2 - 1, 3, 8, 16 no
pAER113a BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 yes
pAER115a BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 yes
pAER125 BL21(DE3) 37 TB1 - 0.5, 1, 2.5, 5 no
pAER113a BL21(DE3) 37 TB1 - 1, 3, 5, 7 no
pAER113a BL21(DE3) 30 TB1 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 23 TB1 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 37 TB2 - 1, 3, 5, 7 no
pAER113a BL21(DE3) 30 TB2 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 23 TB2 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 37 TB3 - 1, 3, 5, 7 yes
pAER113a BL21(DE3) 30 TB3 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 23 TB3 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 37 TB4 - 1, 3, 5, 7 no
pAER113a BL21(DE3) 30 TB4 - 3, 5, 7, 9 yes
pAER113a BL21(DE3) 23 TB4 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 37 TB5 - 1, 3, 5, 7 yes
pAER113a BL21(DE3) 30 TB5 - 3, 5, 7, 9 yes
pAER113a BL21(DE3) 23 TB5 - 3, 5, 7, 9 yes
pAER113a BL21(DE3) 37 TB6 - 1, 3, 5, 7 no
pAER113a BL21(DE3) 30 TB6 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 23 TB6 - 3, 5, 7, 9 no
pAER113a BL21(DE3) 37 TB7 - 1, 3, 5, 7 yes
pAER113a BL21(DE3) 30 TB7 - 3, 5, 7, 9 yes
pAER113a BL21(DE3) 23 TB7 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 37 TB1 - 1, 3, 5, 7 yes
pAER115a BL21(DE3) 30 TB1 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 23 TB1 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 37 TB2 - 1, 3, 5, 7 yes
pAER115a BL21(DE3) 30 TB2 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 23 TB2 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 37 TB3 - 1, 3, 5, 7 yes
pAER115a BL21(DE3) 30 TB3 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 23 TB3 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 37 TB4 - 1, 3, 5, 7 yes
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Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER115a BL21(DE3) 30 TB4 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 23 TB4 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 37 TB5 - 1, 3, 5, 7 yes
pAER115a BL21(DE3) 30 TB5 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 23 TB5 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 37 TB6 - 1, 3, 5, 7 no
pAER115a BL21(DE3) 30 TB6 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 23 TB6 - 3, 5, 7, 9 no
pAER115a BL21(DE3) 37 TB7 - 1, 3, 5, 7 yes
pAER115a BL21(DE3) 30 TB7 - 3, 5, 7, 9 yes
pAER115a BL21(DE3) 23 TB7 - 3, 5, 7, 9 yes
pAER119 BL21(DE3) 37 TB3 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 30 TB3 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 23 TB3 - 1, 3, 8, 16 no
pAER119 BL21(DE3) 37 TB4 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 30 TB4 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 23 TB4 - 1, 3, 8, 16 no
pAER119 BL21(DE3) 37 TB5 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 30 TB5 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 23 TB5 - 1, 3, 8, 16 no
pAER119 BL21(DE3) 37 TB6 - 0.5, 1, 2.5, 5 no
pAER119 BL21(DE3) 30 TB6 - 0.75, 1.5, 4, 8 no
pAER119 BL21(DE3) 23 TB6 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 37 TB3 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 30 TB3 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 23 TB3 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 37 TB4 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 30 TB4 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 23 TB4 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 37 TB5 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 30 TB5 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 23 TB5 - 1, 3, 8, 16 no
pAER125 BL21(DE3) 37 TB6 - 0.5, 1, 2.5, 5 no
pAER125 BL21(DE3) 30 TB6 - 0.75, 1.5, 4, 8 no
pAER125 BL21(DE3) 23 TB6 - 1, 3, 8, 16 no
pAER113a BL21(DE3) 37 TB5 - 1, 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 1% glycine 1, 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5
1.5% NaCl 
replacing K-salts 1, 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 50% less K-salts 1, 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 50% more K-salts 1, 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 1% lysine 1, 2, 3, 4, 5, 6 yes
pAER113a C41(DE3) 37 TB5 - 2, 3, 4, 5, 6 no
pAER113a C43(DE3) 37 TB5 - 2, 3, 4, 5, 6 no
pAER113a BL21(DE3) 37 TB5 1% leucine 2, 3, 4, 5, 6 yes
80
Construct E. coli Strain Temp. (ºC) Media Media Additives
Induction 
Length (hr)
Expression 
Observed?
pAER113a BL21(DE3) 37 TB5 1% tryptophan 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 1% histidine 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 37 TB5 1% methionine 2, 3, 4, 5, 6 yes
pAER113a BL21(DE3) 30 TB5 1% lysine 1, 2, 3, 4, 5 yes
pAER113a BL21(DE3) 30 TB5
1% lysine, 100 µM 
FeCl 1, 2, 3, 4, 5 yes
pAER113a BL21(DE3) 30 TB5
1% lysine, 100 µM 
ZnCl2 1, 2, 3, 4, 5 yes
pAER113a BL21(DE3) 30 TB5
1% lysine, 50% 
more K-salts 1, 2, 3, 4, 5 yes
pDZS110 BL21(DE3) 37 LB - 1, 3, 5, 7 no
pDZS110 BL21(DE3) 30 LB - 2, 4, 6, 8 no
pDZS110 BL21(DE3) 37 TB - 1, 3, 5, 7 no
pDZS110 BL21(DE3) 30 TB - 2, 4, 6, 8 no
pDZS110 BL21(DE3) 37 TB5 - 1, 3, 5, 7 no
pDZS110 BL21(DE3) 30 TB5 - 2, 4, 6, 8 no
pDZS110 BL21(DE3) 37 TB5 1% lysine 1, 3, 5, 7 no
pDZS110 BL21(DE3) 30 TB5 1% lysine 2, 4, 6, 8 no
pDZS110 BL21(DE3) 37 TB5
1% lysine, 50% 
more K-salts 1, 3, 5, 7 no
pDZS110 BL21(DE3) 30 TB5
1% lysine, 50% 
more K-salts 2, 4, 6, 8 no
pET-HS-1c BL21(DE3) 30 2×YT - 1, 3, 5 no
pET-HS-1c BL21(DE3) 30 TB - 1, 3, 5 no
pET-HS-1c BL21(DE3) 30 TB5 - 1, 3, 5 no
pET-HS-3a BL21(DE3) 30 2×YT - 1, 3, 5 no
pET-HS-3a BL21(DE3) 30 TB - 1, 3, 5 no
pET-HS-3a BL21(DE3) 30 TB5 - 1, 3, 5 no
Freeze-Thaw Lysis Protocol
Bacterial pellets from small-scale expression tests were prepared for analysis by  Western 
blotting using freeze-thaw lysis in the presence of lysozyme and DNAse I.  Lysis buffer 
was made fresh just prior to use: 50 mM Tris pH 7.5; 150 mM NaCl, 5 mM MgCl2; 1 
EDTA-free protease inhibitor cocktail tablet (Roche) per 50 mL of buffer; 0.1 mg/mL 
lysozyme (Sigma); and 0.1 mg/mL DNAse I (Sigma).  Cell pellets were resuspended in 
100 µL lysis buffer and allowed to incubate at room temperature for 15 min.  Samples 
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were treated with 5 cycles of freeze-thaw, freezing in liquid N2 and thawing at 37 ºC. 
The final thaw was postponed until ~1 hr prior to gel loading.  It was observed that Fpn 
migrated with an anomalously  high molecular weight if boiled in SDS loading dye prior 
to gel loading.  We observed that incubating samples in SDS loading dye at  room 
temperature prevented this anomalous migration. Therefore, 50 µL of 4× reducing SDS-
PAGE dye was added and samples were incubated at room temperature for 1 hr prior to 
loading.  
Anti-His Western Blotting Protocol
SDS-PAGE was performed in SDS running buffer at  150 V until the dye front neared the 
bottom of the gel.  The gel was removed from its casing and washed in Western transfer 
buffer: Laemmli buffer + 10% (v/v) MeOH for >5 min before being assembled into the 
filter sandwich and Western transfer apparatus.  Transfer to nitrocellulose was carried out 
at 90 V for 40 min in a chilled Western transfer apparatus.  The nitrocellulose was then 
removed from the apparatus and blocked in TBST (50 mM Tris pH 7.5, 150 mM NaCl, 
and 0.5% (v/v) Tween 20) + 3% (w/v) bovine serum albumin (BSA, Sigma) for >30 min 
at room temperature. Mouse anti-His primary antibody (GE Healthcare) was added to 
blocking solution at 1:10,000 and incubated at room temperature for 1 hr.  Membranes 
were washed twice for 5 min in TBST.  Membranes were incubated with goat anti-mouse 
alkaline phosphatase-conjugated secondary antibody  (Rockland) in TBST + 1% (w/v) 
BSA at 1:10,000 at room temperature for 1 hr.  Membranes were washed twice for 5 min 
with TBST.  Membranes were briefly washed again with developing buffer (100 mM Tris 
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pH 9.5; 100 mM NaCl; 5 mM MgCl2).  Membranes were developed at room temperature 
in 20 mL developing buffer by adding nitro blue tetrazolium chloride (NBT) (70 µL of 
50 mg/mL NBT in 70% dimethylformamide) and 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) (40 µL of 50 mg/mL BCIP in 100% dimethylformamide).  
Detergent-Extraction Screening of Recombinant Fpn Expressed in E. coli
Wild-type human Fpn construct pAER113a was transformed into BL21(DE3) E. coli and 
was used to inoculate a 50 mL 2×YT culture containing 100 µg/mL kanamycin.  This 
culture was incubated overnight at 37 ºC while shaking at 240 rpm.  The following 
morning, two beveled 2 L flasks, each containing 500 mL of TB5 media with 1% (w/v) 
D-lysine and 100 µg/mL kanamycin and heated to 37 ºC, were inoculated with 10 mL of 
overnight culture.  Inoculated cultures were shaken at 240 rpm at 37 ºC and OD600 was 
monitored routinely.  When the OD600 reached 0.8, the cultures were shifted to a shaking 
incubator at 30 ºC for 15 min before being induced with 0.4 mM IPTG for 3.5 hr.  After 
induction, cells were harvested by centrifugation, their supernatants were removed and 
the cell pellets were split into 5 g portions and frozen at −20 ºC. Five grams of cell paste 
were thawed and resuspended in 30 mL of buffer containing 50 mM  Tris pH 7.5, 150 mM 
NaCl, and 1 tablet of complete EDTA-free protease inhibitors (Roche). Cells were 
disrupted by sonication on ice (settings: flat  tip; 8 rounds of 30-second pulses; power 8; 
25% duty cycle). Undisrupted cells were pelleted by centrifugation at 11,000×g at 4 ºC 
and membranes were spun down from the supernatant at  125,000×g at 4 ºC.  This 
supernatant was discarded and pelleted membranes were resuspended in 12 mL of buffer 
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containing 50 mM Tris pH 7.5, 150 mM  NaCl, and half a tablet of complete EDTA-free 
protease inhibitors, using a Dounce homogenizer. Resuspended membranes were 
aliquotted into 180 µL fractions in 1.5 mL disposable centrifuge tubes. All detergents 
used in this analysis were prepared as 10% solutions in water (table 3.4).  Twenty 
microliters of stock detergent solution was added to each aliquot of resuspended 
membranes, was mixed, and then was allowed to agitate gently  at 4 ºC for 2 hr.  After 
incubating the membranes in detergent, samples were ultracentrifuged at  140,000×g for 
1 hr at 4 ºC.  Thirty  microliters of each supernatant were removed and mixed with 10 µL 
4× SDS-PAGE loading dye and incubated at room temperature for 1 hr before being 
analyzed by Western blot as described above.   
Table 3.4. Detergent screen for bacterial expression tests
Detergent Name Chemical Name
CHAPS 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate
Cholate 3α,7α,12α-Trihydroxy-5β-cholan-24-oic acid, monosodium salt
Deoxycholate 3α,12α-Dihydroxy-5β-cholan-24-oic acid, monosodium salt
Anzergent-3-12 n-Dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate
Anzergent-3-14 n-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate
Cymal-3 3-Cyclohexyl-1-propyl−β−D-maltoside
Cymal-4 4-Cyclohexyl-1-butyl−β−D-maltoside
Cymal-5 5-Cyclohexyl-1-pentyl−β−D-maltoside
Cymal-6 6-Cyclohexyl-1-hexyl−β−D-maltoside
Fos-choline-9 n-Nonylphosphocholine
Fos-choline-10 n-Decylphosphocholine
Fos-choline-12 n-Dodecylphosphocholine
Fos-choline-14 n-Tetradecylphosphocholine
Dodecyldimethyl glycine n-Dodecyl-N,N-dimethylglycine
Fos-choline-16 n-Hexadecylphosphocholine
Cyclofos-7 7-Cyclohexyl-1-heptylphosphocholine
Fos-choline-iso-11 2,8-Dimethyl-5-nonylphosphocholine
LDAO n-Dodecyl-N,N-dimethylamine-N-oxide
Fos-MEA-8 Octylphospho-N-methylethanolamine
Fos-MEA-10 Decylphospho-N-methylethanolamine
Fos-MEA-12 Dodecylphospho-N-methylethanolamine
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Detergent Name Chemical Name
Fosfen-4 Tetraphenylphosphocholine
Fosfen-5 Pentaphenylphosphocholine
Fosfen-9 Nonylphenylphosphocholine
Octyl glucoside n-Octyl−β−D-glucoside
Nonyl glucoside n-Nonyl−β−D-glucoside
HEGA-9 Nonanoyl-N-hydroxyethylglucamide
HEGA-10 Decanoyl-N-hydroxyethylglucamide
MEGA-8 Octanoyl-N-methylglucamide
MEGA-9 Nonanoyl-N-methylglucamide
Nonyl maltoside n-Nonyl−β−D-maltoside
Decyl maltoside n-Decyl−β−D-maltoside
Undecyl maltoside n-Undecyl−β−D-maltoside
Dodecyl maltoside n-Dodecyl−β−D-maltoside
Tridecyl maltoside n-Tridecyl−β−D-maltoside
Tween 20 Polyoxyethylene(20)sorbitan monolaurate
Brij-35 Polyethylene glycol (23) monododecyl ether
Brij-58 Polyethylene glycol (20) monohexadecyl ether
Tween 80 Polyoxyethylene(80)sorbitan monolaurate
C10E6 Polyoxyethylene(6)decyl ether
C10E9 Polyoxyethylene(9)decyl ether
C12E8 Polyoxyethylene(8)dodecyl ether
C12E9 Polyoxyethylene(9)dodecyl ether
C12E10 Polyoxyethylene(10)dodecyl ether
C13E8 Polyoxyethylene(8)tridecyl ether
Triton X-100 α-[4-(1,1,3,3-Tetramethylbutyl)phenyl]-ω-hydroxy-poly(oxy-1,2-ethanediyl)
Triton X-114 α-[(1,1,3,3-Tetramethylbutyl)phenyl]-ω-hydroxy-poly(oxy-1,2-ethanediyl)
Small-Scale Expression, Purification and SEC Detergent Screening of Fpn from E. coli
Wild-type human Fpn construct pAER113a transformed into BL21(DE3) was expressed 
in 500 mL volumes (as described above) and cell paste was divided into 1 g fractions for 
small-scale purification and size exclusion chromatography (SEC) detergent screening. 
All steps were performed on ice or at 4 ºC, unless otherwise indicated. One gram of cell 
paste was resuspended in 7.5 mL of buffer (50 mM Tris pH 7.5, 150 mM NaCl, and 1 
EDTA-free Complete protease inhibitor tablet (Roche) per 50 mL).  Resuspended cells 
were lysed by  sonication on ice (flat tip, power level 8, 45 seconds total process time, 
25% duty  cycle).  Cell debris was removed by  centrifugation at 8,000×g.  Membranes 
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were pelleted at 125,000×g for 1 hr.  The membrane pellet was resuspended in 6 mL of 
the above buffer using a Dounce homogenizer.  Homogenized membranes were 
transferred to a 15 mL plastic conical tube (Falcon).  Fpn was solubilized by adding 1% 
(w/v) detergent and gently agitating ~12 hr at 4 ºC. After the detergent solubilization, 
6 mL of salt-adjustment buffer (50 mM Tris pH 7.5, 425 mM NaCl, 100 mM imidazole 
pH 7.5, and 0.1 % (w/v) detergent) was added such that the final buffer concentration was 
50 mM Tris pH 7.5, 500 mM NaCl, 50 mM  imidazole pH 7.5, and 0.1% detergent.  Pre-
equilibrated Ni-NTA Superflow (Qiagen) resin (~0.25 mL) was added to the mixture and 
Fpn was loaded by  gently  rocking for 3 hr at 4 ºC. Ni-NTA resin slurry was poured over a 
disposable column and the flow through was collected by gravity  flow.  Resin was 
washed with 10 mL Ni-NTA wash buffer (50 mM  Tris pH 7.5, 500 mM NaCl, 50 mM 
imidazole pH 7.5, 2× the critical micelle concentration (CMC) for the detergent being 
tested, and 1 EDTA-free Complete protease inhibitor pellet per 500 mL). Fpn was eluted 
with 10 mL Ni-NTA elution buffer (50 mM  Tris pH 7.5, 50 mM NaCl, 300 mM 
imidazole pH 7.5, detergent at 2× CMC, and 1 EDTA-free Complete protease inhibitor 
pellet per 500 mL).  Eluate was concentrated using a 10,000 molecular weight cut-off 
4 mL Amicon-Ultra spin concentrator (Millipore) to <100 µL volume.  Concentrated 
eluate was centrifuged at 13,000×g for 10 min.  A 50 µL portion was analyzed by SEC 
using a 1.4 mL Superdex 200 SEC column (GE Healthcare) driven by  a SMART System 
FPLC (GE Healthcare) at  50 µL/min in SEC buffer (50 mM  Tris pH 7.5, 150 mM NaCl, 
detergent at 2× CMC, and 1 EDTA-free Complete protease inhibitor pellet per 500 mL). 
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Fractions were collected and analyzed by  SDS-PAGE anti-His Western blot as described 
above.
Large-Scale Expression and Purification of Fpn in E. coli
Sixty-liter expressions were carried out in a New Brunswick fermenter.  BL21(DE3) E. 
coli containing the plasmid pAER113a was expressed in TB5 with 1% lysine and 
100 µg⁄mL kanamycin. The night before fermentation, a 25 mL overnight culture was 
inoculated from a single colony of a fresh transformation.  In the morning, two 2 L flasks 
each containing 1 L of media were inoculated with 10 mL of the overnight culture and 
were grown at 37 ºC until the OD600 reached ~0.4, at  which point it was used to inoculate 
58 L of media warmed to 37 ºC in the fermenter.  The fermenter was run at 300 rpm at 
37 ºC until the OD600 ≈ 0.4 and then the temperature was lowered to 30 ºC and was 
induced by adding 0.1 mM IPTG.  Cells were harvested after 3 hr of induction.
Cells from approximately one-quarter to one-half of a fermenter run were used per 
purification.  The following purification was for ~160 grams of wet cell paste (~half of 
that particular expression). Cells were resuspended by  adding 600 mL resuspension 
buffer: 50 mM Tris pH 7.5; 150 mM NaCl; and 6 complete EDTA-free protease inhibitor 
tablets (Roche). Cells were split into 4 beakers (~175 mL each) and disrupted by 
sonication (on ice, flat tip, power level 10, 25% duty cycle, 2 min per beaker total process 
time). Large cellular debris was spun down at ~12,000×g for 15 min at 4 ºC. The 
membrane-containing supernatant was then ultracentrifuged at 125,000×g for 1 hr at  4 ºC 
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to pellet membranes. The supernatant was discarded and the membrane pellet  was 
resuspended using a Dounce homogenizer in 100 mL resuspension buffer. Dry fos-
choline-16 was added to resuspended membranes to a final concentration of 1.5% and 
solubilization was performed at  4 ºC overnight, with gentle stirring. After solubilization, 
unsolubilized material was pelleted by ultracentrifugation at 125,000×g for 1 hr at 4 ºC. 
The supernatant was carefully removed and its volume measured.  Buffer components 
were carefully added to raise the NaCl concentration to 500 mM  and to add imidazole pH 
7.5 to a concentration of 50 mM.  The final buffer concentration for the solubilized 
protein solution was 50 mM Tris pH 7.5, 500 mM NaCl, 50 mM imidazole pH 7.5, 1.5% 
fos-choline-16 and EDTA-free protease inhibitors.  Two milliliters of pre-equilibrated Ni-
NTA superose beads (Qiagen) were added to the solution and slowly  stirred in batch at 
4 ºC for several hours. Ni-NTA-protein slurry  was loaded onto a glass column by 
peristaltic pump at 0.5 mL/min and 4 ºC, collecting the flow through.  Once fully  loaded 
in the glass column, the beads were washed with 50 mL wash buffer: 50 mM Tris pH 7.5; 
500 mM NaCl; 50 mM  imidazole pH 7.5; 0.01% fos-choline-16; 1/10 EDTA-free 
protease inhibitor tablet.  Fpn was eluted from the Ni-NTA beads with 20 mL low 
imidazole elution buffer (50 mM Tris pH 7.5; 150 mM  NaCl; 150 mM imidazole pH 7.5; 
0.005% fos-choline-16; and 1/25 EDTA-free protease inhibitor tablet), and 20 mL high 
imidazole elution buffer (50 mM Tris pH 7.5; 150 mM  NaCl; 500 mM imidazole pH 7.5; 
0.005% fos-choline-16; and 1/25 EDTA-free protease inhibitor tablet).
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Baculovirus Expression Constructs
Full-length human, mouse, and zebrafish Fpn genes were subcloned into pAcUW51 and 
pBacPAK8 baculovirus shuttle vectors (table 3.5).  Both types of vectors utilized the 
polyhedron promoter to drive Fpn expression and included the consensus KOZAK 
sequence GCCGCCGCC.  Fpn constructs subcloned into the pAcUW51 vector contained 
a C-terminal 6× His tag.  Fpn constructs subcloned into pBacPAK8 contained an N-
terminal Rho tag and C-terminal FLAG tag and/or a 10× His tag (table 3.5). The Rho tag 
is the first 20 amino acids of bovine rhodopsin, and has been shown to boost expression 
for some eukaryotic membrane proteins (Krautwurst et al. 1998). Baculoviruses were 
constructed and supplied by the Caltech Protein Expression Center. Baculoviruses 
constructed from the pBacPAK8 shuttle vectors were done so with ProGreen Baculovirus 
DNA (AB Vector), which included a soluble green fluorescent protein (GFP) driven by 
the p10 promoter.  GFP expression was used to monitor and optimize infection for these 
baculoviruses.
Table 3.5. Baculovirus expression vectors
Plasmid Name Gene or Insert Name Parent Vector N-terminal tag C-terminal tag
pAER105 human Fpn (w.t.) pAcUW51 none His6
pAER106 human Fpn N144H pAcUW51 none His6
pAER107 human Fpn A77D pAcUW51 none His6
Rho-hFpn-His human Fpn (w.t.) pBacPAK8 Rho His10
Rho-mFpn-His mouse Fpn (w.t.) pBacPAK8 Rho His10
Rho-zFpn-His zebrafish Fpn (w.t.) pBacPAK8 Rho His10
Rho-hFpn-His-FLAG human Fpn (w.t.) pBacPAK8 Rho His10-FLAG
Rho-mFpn-His-FLAG mouse Fpn (w.t.) pBacPAK8 Rho His10-FLAG
Rho-zFpn-His-FLAG zebrafish Fpn (w.t.) pBacPAK8 Rho His10-FLAG
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Small-Scale Tests of Fpn Expression in Baculovirus-Infected Insect Cells
High titer virus stocks were generated at  the Caltech Protein Expression Center. 
Suspension-cultured High Five or Sf9 cells (Invitrogen) were grown in ESF 921 media 
(Expression Systems) with 1× penicillin/streptomycin (Gibco) and split daily  in a shaking 
incubator at  27 ºC and shaking at 233 rpm.  Two-liter beveled filter-capped Erlenmeyer 
flasks (Corning) containing 1 L media were seeded with insect cells to a starting density 
of 0.5·106 viable cells/mL and cultured until the density reached ~3.5·106 viable cells⁄mL 
before enough virus to infect over 95% of cells was added.  The infection was allowed to 
proceed for ~48 hr before cells were harvested by centrifugation.  Cells from 1 mL of 
culture at the time of harvest were removed and frozen for later analysis by Western blot, 
probing against the Rho or His tags.  
Sucrose Gradient Analysis of Fpn Expression in Insect Cell Membranes
Fpn constructs Rho-hFpn-His, Rho-mFpn-His, and Rho-zFpn-His were expressed in 1 L 
volumes of High Five insect cells as described above and split into thirds.  The following 
protocol is adapted from Hu and Kaplan, 2000 (Hu and Kaplan 2000). Cells from one-
third of a liter were resuspended in 50 mL ice-cold resuspension/lysis buffer (50 mM Tris 
pH 7.5, 150 mM  NaCl, 2 EDTA-free Complete protease inhibitors (Roche), 1 mM EDTA 
pH 8.0).  Cells were lysed by sonication (flat tip, power level 6, 3 min total process time, 
25% duty cycle) and cellular debris was removed by centrifugation at  12,000×g for 
20 min at 4 ºC.  The supernatant was subject to ultracentrifugation at 125,000×g for 1 hr 
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at 4 ºC to spin down insect cell membranes.  The ultracentrifugation supernatant was 
discarded and the pellet was resuspended with a Dounce homogenizer in 18 mL of 
membrane resuspension buffer (66.7 mM  Tris pH 7.5, 200 mM NaCl, 1 EDTA-free 
Complete protease inhibitor tablet, 1.33 mM EDTA pH 8.0) and 11.5 grams of dry 
sucrose was added and agitated at 4 ºC until fully dissolved.  The final volume of this 
membrane suspension was ~24 mL and the final buffer composition was 50 mM Tris pH 
7.5, 150 mM NaCl, 1 mM EDTA, and 1.4 M sucrose.  A step  sucrose gradient was poured 
into thin-walled Ultra Clear ultracentrifuge tubes (Beckman) as follows: 3 mL 1.6 M 
sucrose; 12 mL 1.4 M sucrose-containing membranes; 12 mL 1.2 M sucrose; 6 mL 0.8 M 
sucrose; and 3 mL 0.4 M sucrose.  Step gradients were subject to ultracentrifugation at 
96,000×g for 2.5 hr at 4 ºC in a L8-80M Ultracentrifuge (Beckman) using a swinging 
bucket SW32 rotor (Beckman).  Insect cell plasma membranes are known to migrate 
between the 0.8 and 1.2 M sucrose steps, whereas ER membranes are known to migrate 
between 1.2 and 1.4 M  sucrose steps (Hu and Kaplan 2000).  We found the junctions 
between these steps to have a buildup of off-white material, and they were harvested by 
puncturing the side of the thin-walled ultracentrifuge tube with a syringe. These layers 
were analyzed by Western blotting against the N- and C-terminal tags. 
Detergent-Extraction Screening of Recombinant Fpn Expressed in Insect Cells
Plasma and ER membrane fractions from one-third liter of baculovirus-infected High 
Five cells were harvested from a step sucrose gradient as described above.  Plasma and 
ER membrane fractions from Rho-mFpn-His constructs were each diluted to 20 mL with 
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dilution buffer (100 mM  Tris pH 7.5, 300 mM NaCl, 2 mM EDTA, and 2 EDTA-free 
protease inhibitor tablets). These fractions were aliquoted into 400 µL fractions and 
50 µL of 10% detergent stocks (table 3.4) were added to each.  The detergent-membrane 
mixtures were allowed to incubate for 12 hr at 4 ºC with gentle agitation.  After the 
detergent incubation, unsolubilized material was pelleted by ultracentrifugation at 
140,000×g for 20 min at 4 ºC.  The supernatant was removed and 15 µL was mixed with 
5 µL reducing SDS-PAGE loading dye and incubated for 1 hr at room temperature before 
Western blot analysis.  
Scaled-up Expression and Purification of Human, Mouse, and Zebrafish Fpn in Insect 
Cells
Expression and purification of human, mouse and zebrafish Fpns in baculovirus-infected 
insect cells was performed as described (Rice et al. 2009). 
Results and Discussion
Recombinant Expression of Human, Mouse, and Zebrafish Fpn in E. coli
Small-scale human, mouse, and zebrafish Fpn expression tests were performed using 20 
different expression constructs (table 3.1), in 5 different strains of E. coli, grown in over 
10 types of expression media (table 3.2), under several different temperatures, induction 
conditions, and induction time points. Over 900 separate expression tests were performed 
(table 3.3) and Fpn expression was monitored by  Western blotting against a His or 
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StrepTagII tag. Expression constructs each contained the full-length human, mouse, or 
zebrafish sequence in the presence of affinity tags on the N- and/or C-termini. We 
focused mainly on utilizing 6× His tags, but also screened constructs containing 
StrepTagII, myc epitope, or maltose binding protein fusions. We reasoned that if Fpn 
were expressed in E. coli and functional as an iron exporter, it might be toxic and thus 
difficult to express at high levels. In an attempt to prevent this toxicity, we also expressed 
two mutant forms of Fpn that had been shown to cause ferroportin disease in humans—
A77D and N144H. At the time of cloning, these mutations had been freshly discovered, 
and we did not know if these mutants were unable to act as exporters, but went ahead and 
included them in our expression testing. Out of twenty  Fpn expression constructs 
screened (table 3.1), we observed expression detectable by  Western blot in only  two—
pAER113a and pAER115a (figure 3.1). The pAER113a construct  encoded the wild-type 
human Fpn gene with N- and C-terminal His tags.   The pAER115a construct encoded the 
N144H human Fpn gene containing an N-terminal His tag and a C-terminal myc-His tag. 
Both pAER113a and pAER115a yielded expression of an Fpn band at ~60 kDa.  Both of 
these expression vectors were constructed from the pET-28b expression plasmid 
(Novagen) driven by  the IPTG-inducible T7 promoter.  Interestingly, pAER113a and 
pAER115a were the only Fpn variants screened with both N- and C-terminal His tags. 
They  were the product of a mis-annealed PCR and were only identified upon sequencing, 
but were added to the library of expression constructs because of their unique tagging 
configurations.  We did not re-clone mouse Fpn, zebrafish Fpn, nor other Fpn mutants 
with both N- and C-terminal His tags to further test bacterial expression of Fpn, however 
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we expect that these other Fpn forms are capable of being expressed in E. coli with His 
tagging on both termini. 
 
While the details of the expression construct played an important part in bacterial 
expression of Fpn, we found that expression strain and media type were observed to be 
similarly  critical parameters for obtaining detectable expression.  We found that 
BL21(DE3) E. coli was suitable for Fpn expression, but we did not observe expression in 
any other bacterial strain tested. Other strains tested include Rosetta(DE3) (Novagen) and 
RosettaBlue(DE3) (Novagen) strains, which express rare E. coli codon machinery and 
have been shown to help boost the expression of some eukaryotic proteins, and 
C41(DE3) and C43(DE3) strains, which have been shown to be capable of over-
expressing eukaryotic membrane proteins (Arechaga et al. 2003). The culture media 
formulation also had an important effect on expression. We tested Fpn expression using 
11 different media formulations (table 3.2). These media formulations were based on the 
common media formulations known as LB, SOC, 2×YT, and TB. The media formulations 
TB1-TB7 (also called GM1-GM7) were developed by Yan Poon (Poon 2008).  They  were 
derivatives of TB where some or all of the yeast extract was replaced with malt and/or 
beef extracts (table 3.2). Fpn expression was observed in some conditions with the TB, 
TB1, TB2, TB3, TB4, TB5, and TB7 media formulations, but not in the 2×TY, LB, SOC, 
or TB6 media formulations (table 3.3).
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After screening and optimizing Fpn expression as described above, the best expression 
condition observed was using the pAER113a or pAER115a vector, BL21(DE3) strain, 
grown in TB5 media and induced at 30 ºC for 3 hr.  We sought to further enhance 
expression by varying amino acid and salt additives in this formulation.  We varied the 
salts in TB5 by increasing or reducing the amount of potassium phosphate salt solution or 
by replacing them with sodium chloride. Separate tests screened amino acid additives, 
where pure powdered L-glycine, L-lysine, L-tryptophan, L-leucine, L-histidine, or L-
methionine were added to a level of 1% (w/v). Fpn expression was observed in all these 
tests, and the addition L-lysine lead to a small increase in expression (figure 3.2). Further 
tests were performed to test  if the further addition of 100 µM FeCl2 or ZnCl2 would 
increase expression, however they did not. 
 
The final optimized and scaled-up Fpn expression condition in E. coli was in BL21(DE3) 
cells transfected with pAER113a, grown in TB5 media with an additional 1% L-lysine, 
and induced by 0.1 mM IPTG for 3 hr at 30 ºC.  Typical 55 L fermenter runs yielded 
~320–350 grams of wet bacterial cell paste.
Boiling Fpn in Loading Dye Results in Aberrant SDS-PAGE Migration
Fpn expressed in E. coli was found to run at an anomalously high molecular weight if 
SDS-PAGE sample preparation protocol involved the usual 95–100 ºC incubation in 
SDS-containing loading dye.  Under these conditions Fpn was observed to run at an 
apparent molecular weight  of 150–250 kDa (figure 3.3).  Fpn samples incubated at room 
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temperature for >20 min were shown to migrate with an apparent mass of 60 kDa, which 
was much closer to the predicted Fpn molecular weight of 65–70 kDa (depending on 
affinity tag configuration).  Unless otherwise noted, Fpn samples analyzed by SDS-PAGE 
for subsequent Coomassie staining or Western blotting were all incubated at room temp 
for 20 min to 1 hr prior to loading.  
Detergent-Extraction of Recombinant Fpn from E. coli Membranes
Human Fpn expressed in BL21(DE3) from the expression plasmid pAER113a was 
screened for its ability to be solubilized by 48 detergents as described above (table 3.4). 
Membranes solubilization was performed at 4 ºC for 2 hr, after which unsolubilized 
material was centrifuged and supernatants were analyzed by  Western blot, probing with 
an anti-His antibody  against the affinity tags on this Fpn construct.  Comparing detergent 
extractions with non-detergent controls allowed for the clear identification of small 
amounts of solubilized Fpn in the presence of a subset of detergents screened. The 
detergents fos-choline-14, fos-choline-16, cyclofos-7, anzergent-3-12, anzergent-3-14, 
and to a lesser extent cymal-4, were capable of extracting Fpn from bacterial membranes 
to yield a band at ~60 kDa as detected by Western blot (figure 3.4).  Interestingly, the 
Western blots of this analysis revealed that some detergents extracted Fpn in a form that 
was aggregated at >200 kDa as determined by SDS-PAGE, much like the bands observed 
when samples are boiled in SDS-PAGE loading dye.  These high molecular weight Fpn 
aggregates were detected by  Western blot upon solubilization with the detergents 
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anzergent-3-14, fos-choline-10, -12, -14, and -16, LDAO, dodecyldimethyl glycine, 
cyfos-7, and almost all polyoxyethylene detergents (table 3.6) (figure 3.4).  
Table 3.6. Detergent extraction of Fpn expressed in E. coli and insect cells 
Detergent Name
Bacterial Expression Insect Cell Expression
Extracted As: Extracted As:
60 kDa band Aggregates 60 kDa band Aggregates
CHAPS   +  
Cholate   +  
Deoxycholate   +  
Anzergent-3-12 +  + +
Anzergent-3-14 + + + +
Cymal-3   +  
Cymal-4  n.d. n.d.
Cymal-5 +  +  
Cymal-6   +  
Fos-choline-9   n.d. n.d.
Fos-choline-10  + + +
Fos-choline-12  + + +
Fos-choline-14 + + + +
Dodecyldimethyl glycine  + + +
Fos-choline-16 + + +  
Cyclofos-7 + + n.d. n.d.
Fos-choline-iso-11   n.d. n.d.
LDAO  + + +
Fos-MEA-8   +  
Fos-MEA-10   +  
Fos-MEA-12   +  
Fosfen-4   +  
Fosfen-5     
Fosfen-9   n.d. n.d.
Octyl glucoside     
Nonyl glucoside     
HEGA-9   + +
HEGA-10     
MEGA-8     
MEGA-9   +  
Nonyl maltoside   +  
Decyl maltoside   +  
Undecyl maltoside   +  
Dodecyl maltoside   +  
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Detergent Name
Bacterial Expression Insect Cell Expression
Tridecyl maltoside   +  
Tween 20  + +  
Brij-35  + +  
Brij-58  + + +
Tween 80     
C10E6  + n.d. n.d.
C10E9  + + +
C12E8  + + +
C12E9  + + +
C12E10  + + +
C13E8  + + +
Triton X-100  + + +
Triton X-114  + n.d. n.d.
Based on these results, a subset of the detergents screened was selected to move forward 
with small-scale preparations of Fpn.  Samples were solubilized, purified by Ni-affinity 
chromatography, and analyzed by analytical size exclusion chromatography  (SEC) using 
a 1.4 mL Superdex 200 column (GE Healthcare) performed using a Smart  System FPLC 
(GE Healthcare), as described in the methods.  The detergents chosen for the next phase 
of analysis included each detergent that  was capable of extracting Fpn as an 
approximately 60 kDa band in the solubilization screen (fos-choline-14, fos-choline-16, 
cyclofos-7, anzergent-3-12, anzergent-3-14, and cymal-4), as well as a subset  of the 
detergents that were shown to extract  Fpn as a high molecular weight band (fos-
choline-10, and fos-choline-12). Analytical SEC profiles revealed that fos-choline-14 and 
fos-choline-16 were capable of stabilizing solubilized Fpn as a predominantly  single 
peak, suggesting a single species, though without accurate knowledge of the detergent 
micelle size, we were not capable of determining the oligomeric state of solubilized Fpn 
with these data (figure 3.5).  The analytical SEC trace for the fos-choline-16 
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solubilization was the most symmetric, with the fos-choline-14 solubilization having a 
small high molecular weight shoulder in its trace.  Extracting with fos-choline-12 
revealed a complicated trace with much more material eluting at higher molecular 
weights, as well as in the void volume.  We found that fos-choline-10 was poor at 
solubilizing Fpn from these membranes, with the little Fpn that was extracted being 
observed in the void volume.  Cyclofos-7 was also a very  poor Fpn extractor as assessed 
by this method.  Anzergent-3-12 and anzergent-3-14 both yielded complicated SEC 
traces, indicative of heterogeneity in the aggregation state of these Fpn samples. We 
concluded that fos-choline-16 was the best detergent for the solubilization of Fpn from 
bacterial membranes into a homogenous population of solubilized protein-detergent 
complexes.  
Purification of Recombinant Fpn from E. coli
Doubly His-tagged Fpn was expressed in BL21(DE3) E. coli as described above.  Cells 
were harvested, lysed by sonication and whole-cell membranes were separated from 
soluble proteins and cellular debris by centrifugation.  Purified membranes were 
incubated with fos-choline-16 detergent to extract  Fpn and then unsolubilized membranes 
were removed by  centrifugation. Fpn was then purified by Ni affinity  chromatography 
and eluted with imidazole (figure 3.6). After Ni chromatography, Fpn purity was assessed 
by SDS-PAGE to be ~50%–60%.  Fpn expression was verified by  Western blotting 
against the His tag, as well as by proteolytic peptide sequencing by  mass spec at the 
PPMAL facility  in the Beckman Institute at Caltech.  Yields were estimated at ~10–30 µg 
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purified Fpn per liter of bacterial culture.  Further purification efforts using ion exchange 
chromatography  or SEC were made as well, however due to the low initial yield, protein 
losses during these extra steps resulted in very little final protein.  While the bacterial 
expression of Fpn was possible, it was not suitable for its production in milligram 
quantities at high purity for biophysical analysis and crystallization attempts.  
Recombinant Expression of Human, Mouse, and Zebrafish Fpn in Insect Cells
Small-scale tests screening the expression of human, mouse and zebrafish Fpn were 
carried out  in shaking flasks of High Five cells grown in suspension.  Baculoviruses used 
to infect these insect cells (table 3.5) encoded Fpn variants with or without an N-terminal 
Rho tag (Krautwurst et al. 1998). Each baculovirus tested utilized the polyhedron 
promoter to drive Fpn expression.  We observed Fpn expression by Western blot for each 
baculovirus containing an N-terminal Rho tag, whereas no Fpn expression was observed 
for baculoviruses coding for Fpn lacking this tag.  Western blotting was performed using 
probes against both the N-terminal Rho tag and C-terminal affinity tags, verifying full-
length Fpn expression (figure 3.7).  Differences between the C-terminal affinity tags 
included in these constructs had minimal effect  on expression levels.  Constructs with 
either a 10× His tag or a 10× His tag in tandem with a FLAG tag were expressed at 
similar levels.  Furthermore, the three Fpn homologues were found to express at 
comparable levels, as determined by Western blot.  Both High Five (derived from 
Trichoplusia ni) and Sf9 (derived from Spodoptera frugiperda) insect cell lines were 
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capable of expressing Fpn (figure 3.7), however all scaled-up expressions were 
performed in High Five cells (Rice et al. 2009).
While full-length Fpn expression was observed when baculovirus-infected insect cells 
were analyzed by Western blot, we sought to learn the subcellular location of this 
expressed Fpn.  In particular, we wanted to determine if Fpn was fully processed and 
transported to the plasma membrane, or if it  was building up  within the cell at a 
processing organelle such as the endoplasmic reticulum.  To assess the location of Fpn 
within these insect cells, we performed a coarse sucrose gradient fractionation.  We 
observed that a large fraction of the expressed Fpn was fully  processed and trafficked to 
the plasma membrane, with some significant fraction present in the ER (figure 3.8). 
These results indicated that insect cells were capable of expressing, processing and 
trafficking human, mouse, and zebrafish Fpn to the plasma membrane.  Because we 
observed such a large fraction of Fpn in the plasma membrane, we suggest that  the Fpn 
contained within subcellular compartments was proceeding along the biosynthetic 
pathway without significant bottlenecks.  
Detergent Extraction of Recombinant Fpn from Insect Cell Membranes
In contrast to bacterially expressed Fpn, which was only capable of being extracted by a 
few detergents, insect  cell–expressed Fpn was broadly extractable by many detergents 
screened (table 3.6) (figure 3.9).  Some detergents, such as cymals, maltosides, fos-
choline-16, fos-MEAs, and MEGA-9, extracted Fpn as a band migrating with an apparent 
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mass of ~60 kDa with little to no aggregate observed by Western blot.  Other detergents, 
such as the lower chain length fos-cholines, polyoxyethylenes, anzergents and LDAO, 
were capable of extracting Fpn as an ~60 kDa band, but also extracted a significant 
portion of Fpn as aggregates (table 3.6).  These high molecular weight aggregates were 
not observed in samples treated without detergent, and perhaps suggests that some 
detergents extract Fpn in a partially unstable form tending toward aggregation.  
Purification of Recombinant Fpn from Insect Cells
The expression, detergent extraction, and purification of human Fpn to levels suitable for 
biophysical characterization has been described (Rice et al. 2009).  Mouse and zebrafish 
Fpns were purified using identical methods, with similar results (figures 3.10 and 3.11). 
Numerous crystallization attempts (>5,000) were carried out with purified human, mouse 
and zebrafish Fpn (see appendix), however no Fpn crystals were observed.  
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Figure 3.1.  Western blot of small-scale bacterial expression of wild-type (panel A) and 
N144H (panel B) Fpns. As described in the methods, BL21(DE3) E. coli were 
transformed with either pAER113a or pAER115a, cultured in TB5 media at 37 ºC, shifted 
to the final temperature, induced with IPTG, and harvested after the time shown, in hours. 
Panel C shows a schematic depicting the tagging orientation of the constructs used.  The 
~60 kDa Fpn bands are indicated (red arrows).
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Figure 3.2. Western blot of test for the affect of growth media additives to bacterial 
cultures.  BL21(DE3) E. coli was transformed with wild-type Fpn (pAER113a) and was 
cultured in TB5 media with 1% L-glycine, 1% L-lysine or 50% extra salt as additives, as 
indicated in the methods.  Induction length is indicated in hours, for each lane.  “Control” 
is expression in TB5 media alone.  The ~60 kDa Fpn bands are indicated (red arrow).
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Figure 3.3.   Boiling samples in loading dye leads to aberrant SDS-PAGE migration.  A 
Western blot is shown for an expression time course of N144H Fpn (pAER115a) in 
BL21(DE3) E coli.  Samples loaded in the “boiled” or “room temp” lanes were taken 
from the same time course, with the only difference being their treatment immediately 
prior to gel loading.  Samples were either boiled in loading dye for 1 min or incubated at 
room temperature for 1 hr prior to SDS-PAGE.  Induction length is indicated in hours, for 
each lane.  The ~60 kDa Fpn band is noted by a red arrow. 
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Figure 3.4. Detergent solubilization screen of Fpn expressed in BL21(DE3) E.coli. 
Samples were incubated in water or 1% detergent and Western blots against the His tag 
were performed.  Fpn bands at ~60 kDa are noted by red arrows.  See table 3.6 for a full 
summary of these data.
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Figure 3.5.  Quality  analysis by SEC for fos-choline extraction of Fpn from E. coli 
membranes. Fos-choline 10, 12, 14, and 16 were used to extract Fpn from BL21(DE3) E. 
coli.  Extracts were purified by Ni affinity chromatography, concentrated, and analyzed 
by SEC using a SMART system FPLC.  Traces for molecular weight standards are shown 
in gray or black for reference (MW1 and MW2), and the molecular weight, in kDa, 
corresponding to each peak is labeled. 
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Figure 3.6. Ni-NTA purification of N144H human Fpn (pAER115a) expressed in 
BL21(DE3) E. coli.  Purified Fpn was eluted with imidazole (see Methods) and 5, 15, or 
30 µL were loaded on a 12% polyacrilamide gel and analyzed by SDS-PAGE.  Coomasie 
staining revealed a Fpn band at ~60 kDa (red arrow).  Molecular weight standards are 
shown at left and labeled in kDa.   
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Figure 3.7.  Expression of Fpn in baculovirus-infected insect  cells.  Baculoviruses 
encoding full-length human, mouse, or zebrafish Fpn with an N-terminal Rho tag and a 
C-terminal His tag (H, M, and Z, respectively) or only a C-terminal His tag (H (no rho)), 
were used to infect Sf9 and High Five insect cells.    Cells were harvested 48 hr post-
infection and Westerns against the His (panel A) or Rho (panel B) tags were performed. 
Molecular weight markers are labeled on the left in kDa.  Panel C shows a schematic 
depicting the tagging orientation of the constructs used. 
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Figure 3.8.  Sucrose gradient of membranes from Fpn-expressing baculovirus-infected 
insect cells.  A Western blot against the Rho tag of human, mouse, and zebrafish Fpn 
reveals that Fpn was found in both plasma membrane (PM) and endoplasmic reticulum 
(ER) fractions.  Molecular weight standards are shown in kDa.
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Figure 3.9. Detergent solubilization screen of Fpn expressed in insect cells. 
Solubilization was performed in water (“no det.”) or 1% detergent (see methods) and 
Western blots against  the Rho tag were performed.  Fpn bands at ~60 kDa were observed 
for solubilization for many detergents tested.  See table 3.6 for a full summary of these 
data.
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Figure 3.10. Coomassie-stained SDS-PAGE analysis of purified Fpn expressed in 
baculovirus-infected High Five cells.  Full-length human, mouse and zebrafish Fpn with 
an N-terminal Rho tag, and a C-terminal tandem 10×His-FLAG tag were expressed in 
insect cells.  Panel A shows human, mouse, and zebrafish Fpns after TALON and FLAG 
column purification.  Panel B shows human and mouse Fpns after an additional SEC 
separation.  Molecular weight standards are shown at left and labeled in kDa.
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Figure 3.11.  SEC analysis of mouse Fpn after purification over TALON and FLAG 
columns.  The mouse Fpn elution profile is a symmetrical peak with a small high 
molecular weight shoulder. 
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Chapter 4:
Lack of Evidence for Interactions between Ferroportin and 
the Hereditary Hemochromatosis Protein, HFE
In this chapter we report various assays aimed at detecting a physical and/or functional 
interaction between Fpn and HFE.    
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Introduction
Since the initial identification and cloning of the HFE gene, its precise role in iron 
homeostasis has been a mystery  (Feder et al. 1996).  Clearly HFE plays a critical role in 
regulating iron stores, as recessive mutations within this gene were shown to account for 
the majority of worldwide hereditary  hemochromatosis (HH) (Feder et al. 1996).  It was 
also shown that HFE interacted with transferrin receptor (TfR), that this binding reduced 
TfR's affinity  for transferrin (Tf), and that the disease-causing HFE mutations interfere 
with this interaction (Feder et al. 1998).  The discovery of the HFE-TfR interaction gave 
clear evidence that HFE could play a role in regulating cellular iron levels by modulating 
the TfR-Tf iron uptake pathway, but it  was still unclear how mutations in HFE might lead 
to the severe iron overload observed in HH patients.  In 2000, three groups independently 
identified the only known vertebrate ionic iron exporter, ferroportin (Fpn) (Abboud and 
Haile 2000; Donovan et al. 2000; McKie et al. 2000).  It was shown that both HFE 
(Parkkila et al. 1997) and Fpn (Donovan et al. 2000) are expressed on the basolateral 
membrane of duodenal enterocytes, the main site of systemic iron uptake.  It was also 
noted that HFE expression in the duodenum was highest in the duodenal crypt cells 
(Parkkila et al. 1997), whereas Fpn expression was highest at the villus tips, though still 
present in the crypts at lower levels (Donovan et al. 2000).  It  had been hypothesized that 
body iron stores were sensed in the duodenal crypt cells (Roy and Enns 2000), and this 
lead Townsend and Drakesmith to introduce the hypothesis that HFE could act as an iron 
sensor by negatively regulating the functions of both TfR and Fpn in duodenal crypt cells 
119
(Townsend and Drakesmith 2002).  A schematic for this hypothesis is depicted in figure 
4.1.  In brief, the hypothesis predicted that HFE was capable of reducing iron uptake by 
binding to and inhibiting the iron export function of Fpn.  It suggested that HFE could 
bind to either TfR or Fpn and these three proteins (along with serum Tf) were in a 
dynamic equilibrium on the basolateral serum-facing membrane (figure 4.1A).  If iron 
stores in an individual were low (and thus Tf iron saturation was low) then Tf would be 
unable to bind tightly  to TfR at the cell surface, and thus HFE would be sequestered by 
TfR.  This would prevent HFE from binding to and inhibiting Fpn and would allow iron 
uptake to proceed as normal (figure 4.1B).  On the other hand, if iron stores were high 
(and thus Tf iron-saturation was high) Tf would bind tightly  to TfR, competing away any 
HFE.  HFE would then be allowed to bind Fpn and iron uptake would be prevented 
(figure 4.1C).  This hypothesis was further strengthened by a study in macrophage-like 
cells reporting that soluble HFE added to iron-loaded cells was capable of inhibiting iron 
export (Drakesmith et al. 2002).  Following from this, I pursued a line of investigation 
aimed at identifying a physical or functional interaction between Fpn and HFE.  While I 
was ultimately unsuccessful, the experiments described here may prove useful for future 
scientists interested in pursuing a similar line of research.  
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Materials and Methods
Analytical Size-Exclusion Chromatography
Analytical size-exclusion chromatography (SEC) was performed using a SMART system 
FPLC (GE Healthcare) with a 1.4 mL Superdex 200 column (GE Healthcare) with a flow 
rate of 50 µL/min equilibrated in 50 mM Tris pH 7.5, 150 mM NaCl, 0.05% fos-
choline-16, and EDTA-free protease inhibitors (Roche).  His-tagged human Fpn was 
expressed in one liter of pAER113a-transformed BL21(DE3) E. coli grown in TB5 media 
(see chapter 3).  Fpn was solubilized in fos-choline-16, purified by  Ni-NTA 
chromatography  as described in chapter 3, concentrated to ~120 µL, centrifuged at 
16,000×g for 10 min, and then split into two 60 µL fractions. Soluble HFE was purified 
from Chinese hamster ovary (CHO) cell supernatants as described (Lebrón et al. 1998). 
One Fpn-containing fraction was mixed with soluble HFE at a concentration of 18 µM. 
No additions were made to the other Fpn fraction and it acted as the Fpn-only control.  A 
similar control for HFE alone was prepared by diluting it as above into 60 µL running 
buffer.  All samples were incubated at 4 ºC for 3 hr prior to size-exclusion 
chromatography.  SEC was performed by injecting 50 µL of each sample over the column 
in sequence. Traces were compared to molecular weight standards of known mass run in 
similar conditions: Blue Dextran (2000 kDa), thyroglobulin (670 kDa), ferritin 
(440 kDa), catalase (200 kDa), and albumin (67 kDa) (all standards from GE Healthcare's 
SEC MW standard kit). 
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Testing for binding between Fpn and HFE by surface plasmon resonance
Experiments evaluating the interaction between human Rho-Fpn-His and soluble human 
HFE were performed at 10 ºC using a Biacore 2000 Instrument (GE Healthcare). 
Interactions between immobilized Fpn on a sensor chip  and soluble HFE injected over 
the sensor surface were monitored in real time as response units (RU).  Biosensor chips 
were prepared as described in chapter 2 (Rice et al. 2009).  Briefly, two flow cells of a 
CM5 biosensor chip were prepared by covalently  coupling ~2000 RU of B630N mouse 
monoclonal anti-Rho antibody. Rho-Fpn-His expressed in baculovirus-infected insect 
cells was purified by Ni-NTA metal affinity  chromatography followed by size-exclusion 
chromatography  in 50 mM  Tris pH 7.5, 150 mM NaCl, 0.2% (w/v) DM and injected over 
the anti-Rho surface, capturing ~500 RU to the antibody surface of one flow cell, leaving 
the other flow cell as antibody-only  reference. After capturing Fpn, the sensor surface 
was monitored for 3 hr in the same buffer at a flow rate of 5 µL/min, at which time Fpn 
was slowly shedding from the surface at a constant rate of ~0.3 RU/min. A serial dilution 
series of HFE was prepared (15.1 µM, 7.55 µM, and 3.775 µM) by  diluting concentrated 
HFE in the above buffer.  Samples containing 0, 3.775, 7.55, and 15.1 µM HFE were 
injected simultaneously over control and experimental surfaces at 5 µL/min for 90 s and 
then allowed to dissociate for an additional 90 s.  Sensorgrams were analyzed in Scrubber 
(BioLogic Software Pty. Ld.).
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Transferrin Iron-Loading
Aqueous solutions of ferric iron chloride (FeCl3, 25 mM) and nitrilotriacetic acid (NTA, 
50 mM) were freshly  prepared and filtered at 0.22 µm.  Dry human holo-transferrin (Tf, 
Sigma) was dissolved in 1.5 mL 100 mM ammonium bicarbonate and filtered at 0.22 µm. 
Tf concentration was approximated spectrophotometrically  to be 150 µM  using an 
extinction coefficient of 5000 cm−1 M−1 for absorbance at 454 nm.  Buffer was prepared 
by mixing 100 mM ammonium bicarbonate, adjusting its pH to 7.5, and filtering at 
0.22 µm.  Two milliliters of 1:2 FeCl3·NTA were prepared by mixing 1 mL FeCl3 with 
1 mL NTA solutions.  The FeCl3·NTA levels of the Tf solution were raised to 300 µM by 
adding 36.9 µL 12.5 mM FeCl3·NTA to the 1.5 mL Tf solution.  Tf was incubated in the 
presence of FeCl3·NTA for 2 hr before excess FeCl3·NTA was removed by overnight 
serial dialysis in 100 mM ammonium bicarbonate, pH 7.5.  After dialysis, the 
concentration of iron-loaded Tf was again measured and the degree of iron incorporation 
was estimated to be complete by the ratio of spectrophotometric absorbances at 465 and 
280 nm equaling approximately 0.050 (A465/A280 = 0.052) (He and Mason 2002).
Investigating a Possible Effect by HFE on the Hepcidin-Induced Internalization of Fpn
HeLa cells were grown in Dulbelcco's modified Eagle's medium containing 4.5 g/L of D-
glucose, 4 mM L-glutamine, 110 mg/L of sodium pyruvate (Gibco), with 1× penicillin/
streptomycin (Gibco), and 10% (v/v) fetal bovine serum (Atlanta Biologicals).  All 
transfections were performed using lipofectamine 2000 (Invitrogen) as per the 
manufacturer's instruction.  HeLa cells were seeded onto poly-L-lysine-treated glass 
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coverslips in 6-well format (0.5·106 cells/well), transfected with human Fpn-GFP the 
following day, and then ~20 hr post-transfection were used to test  the effects of soluble 
human HFE on the hepcidin-induced internalization of Fpn. All internalizations were 
performed in growth media supplemented with cycloheximide, hepcidin-25 (Bachem), 
and/or soluble human HFE purified from CHO supernatants as described (Lebrón et al. 
1998).  Internalizations were performed after a 2 hr 75 µg/mL cycloheximide 
pretreatment, followed by  4 hr of 0 or 2 µM  hepcidin-25 (Bachem) internalization, as 
described (Rice et al. 2009).  As measured relative to the start of the hepcidin-25 
incubation, HFE incubation time was initiated at t equals −2, −0.5, and 0 hr.  HFE was 
added at a concentration of 300 nM.  At the 4 hr time point after hepcidin-25 addition, the 
internalization was stopped by  quickly washing three times with PBS followed by 20 min 
of fixing in 4% PFA at room temperature.  After fixing, the cover slips were mounted in 
DAPI-containing Prolong Gold anti-fade mounting media (Invitrogen), sealed with nail 
polish, and then imaged by confocal fluorescence microscopy. Imaging was performed on 
an UltraVIEW ERS Rapid Confocal Imager (Perkin-Elmer) using a 100× objective lens 
(αPlan-APOCHROMAT 1.46 Oil DIC, Zeiss).  Full confocal stacks were imaged for 
GFP fluorescence at 0.25 µm spacing in z and representative slices are shown.
Internalization reactions were repeated, as above, with an increased HFE concentration 
(690 nM) and an excess of iron-loaded Tf (400 nM) to saturate transferrin receptor (TfR) 
and out-compete its HFE-binding capabilities.  Tf was added 30 min prior to hepcidin-25 
addition. HFE was added 15 min prior to hepcidin-25 addition.  This set of experiments 
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varied hepcidin-25 concentration, testing 0 or 2 µM hepcidin-25 concentrations. 
Incubations were stopped, fixed, mounted, and imaged as described above.
Results and Discussion
Analytical Size-Exclusion Chromatography
The potential binding between wild-type human Fpn expressed and purified from E. coli 
and soluble human HFE expressed in CHO cells was assessed by  analytical SEC (figure 
4.2).  As described in chapter 3, Fpn extracted in fos-choline-16 elutes as a broad peak 
centered at approximately 1.2 mL (see chapter 3, figure 3.5).  We found that soluble HFE 
eluted as a symmetrical peak centered at approximately 1.6 mL (figure 4.2). Fpn and HFE 
were pre-mixed at a high HFE concentration (18.2 µM).  After pre-incubation the mixture 
was analyzed by analytical SEC, however no evidence of a Fpn-HFE complex was 
detected (see figure 4.2, blue curve).  
These results are not conclusive.  If fos-choline-16 interfered with an Fpn-HFE 
interaction, we would expect to not detect it under these conditions.  Also, Fpn contains 
potential glycosylation sites (Devalia et al. 2002) and these carbohydrate moieties would 
be absent in bacterially expressed Fpn.  If glycosylation of Fpn was necessary for an 
interaction with HFE, we would not expect to observe binding in this assay.  Finally, a 
weak interaction might not be detectable by a technique like analytical SEC, which 
allows time for dissociation before detection.
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Testing for an Interaction between Fpn and HFE by Surface Plasmon Resonance
The potential binding between wild-type human Fpn expressed and purified from 
baculovirus-infected insect cells and soluble human HFE was assessed by surface 
plasmon resonance (figure 4.3).  Rho-tagged Fpn was coupled to an anti-Rho antibody 
surface, soluble HFE was injected at various concentrations (0–15.1 µM HFE), and the 
response was continuously monitored in an effort to detect binding.  Despite high levels 
of HFE injected over the Fpn surface, no binding was observed (figure 4.3).  
As with the analytical SEC experiments above, these results are not fully  conclusive. 
Unlike analytical SEC, surface plasmon resonance is capable of detecting weak 
interactions with quick dissociation rates, however detergent or improper glycosylation 
could still be potentially interfering with a Fpn-HFE interaction.  
Investigating a Possible Effect by HFE on Hepcidin-Induced Internalization of Fpn
We were unable to detect an interaction between Fpn and HFE with biophysical methods 
using detergent solubilized Fpn, and thus we moved on to cell-based assays.  In these 
experiments we attempted to detect a functional interaction between Fpn and HFE.  After 
developing a hepcidin-induced Fpn-GFP internalization assay in HeLa cells (Rice et al. 
2009), we asked if this internalization was disrupted in the presence of soluble HFE.  We 
used 300 nM  HFE, a concentration shown to have an inhibitory effect on iron export in 
macrophage-like cells (Drakesmith et al. 2002).  In this experiment we asked whether 
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soluble HFE would prevent the internalization of Fpn-GFP by hepcidin-25; however we 
saw no internalization defect (figure 4.4).  This internalization assay was performed in the 
presence of Tf-containing fetal calf serum, however to ensure that our HFE was not being 
sequestered by  endogenous TfR on the surface of these cells, we performed another 
experiment with elevated HFE concentration (690 nM) and an additional 400 nM  iron-
loaded human Tf added on top of the bovine Tf that is naturally present in the serum 
(figure 4.5).  Under these conditions, hepcidin-induced internalization of Fpn was not 
prevented.   
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Figure 4.1.  Townsend-Drakesmith HFE hypothesis.  A regulatory role for HFE is 
proposed whereby a dynamic equilibrium exists between HFE, Fpn, TfR, and iron-loaded 
Tf on the basolateral membrane of duodenal crypt cells.  Panel A depicts this hypothetical 
equilibrium.  When Tf saturation is low (panel B), HFE binds TfR and iron is exported. 
When Tf saturation is high (panel C), HFE is unable to bind TfR and instead binds Fpn, 
inhibiting iron export.  Figure adapted from Townsend and Drakesmith 2002.  
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Figure 4.2.  Potential interactions between bacterially expressed Fpn and soluble HFE 
was screened by analytical size-exclusion chromatography as described in the methods. 
Traces for molecular weight standards are shown (MW 1 in black and MW 2 in grey) and 
are labeled in kDa.  
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Figure 4.3. Potential interactions between Fpn expressed in baculovirus-infected insect 
cells and soluble HFE were screened by surface plasmon resonance.  A dilution series of 
soluble human HFE (0, 3.8, 7.8, and 15.1 µM) was injected over a biosensor surface 
containing ~500 RU human Rho-Fpn-His.  Reference-subtracted response curves are 
shown.
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Figure 4.4.  Fpn-GFP was transiently transfected into HeLa cells, as described in the 
methods.  Hepcidin-induced internalization of Fpn-GFP was performed in the presence of 
300 nM HFE and analyzed by confocal microscopy.  HFE was added either 2 hr prior to, 
30 min prior to, or together with hepcidin-25 addition.
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Figure 4.5.  Fpn-GFP was transiently transfected into HeLa cells, as described in the 
methods.  Under conditions of Tf saturation (400 nM iron-loaded Tf) hepcidin-induced 
internalization of Fpn-GFP was performed in the presence or absence of 690 nM HFE 
and analyzed by confocal microscopy.
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Appendix:
Crystallization Attempts of Ferroportin and the
Ferroportin:Hepcidin-25 Complex   
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Construct Detergent Purification Conc.  (mg/mL)
Temp. 
(ºC) Screen Method
Rho-hFpn-His DDM TALON 11 20 Index vapor diffusion
Rho-hFpn-His DDM TALON 11 20 Wizard I&II vapor diffusion
Rho-hFpn-His DDM TALON 11 20
Crystal Screen 
I&II vapor diffusion
Rho-hFpn-His DDM TALON 11 20 Cation Screen vapor diffusion
Rho-zFpn-His DDM TALON 4 20 Index vapor diffusion
Rho-zFpn-His DDM TALON 4 20 Wizard I&II vapor diffusion
Rho-zFpn-His DDM TALON 4 20
Crystal Screen 
I&II vapor diffusion
Rho-zFpn-His DDM TALON 4 20 Cation Screen vapor diffusion
Rho-zFpn-His DDM TALON 4 20 Cryo I&II vapor diffusion
Rho-zFpn-His DDM TALON 8 20 PEG I vapor diffusion
Rho-zFpn-His DDM TALON 8 20 PEG II vapor diffusion
Rho-zFpn-His DDM TALON 8 20 Index vapor diffusion
Rho-zFpn-His DDM TALON 8 20
Crystal Screen 
I&II vapor diffusion
Rho-zFpn-His DDM TALON 8 20 Salt Rx vapor diffusion
Rho-zFpn-His DDM TALON 8 20 pH Clear vapor diffusion
Rho-zFpn-His DDM TALON 10 20
Crystal Screen 
I&II vapor diffusion
Rho-zFpn-His DDM TALON 10 20 Memfac vapor diffusion
Rho-zFpn-His DDM TALON 10 20 PEG Ion vapor diffusion
Rho-zFpn-His DDM TALON 10 20 Wizard I&II vapor diffusion
Rho-zFpn-His DDM TALON 10 20 Index vapor diffusion
Rho-zFpn-His + 0.16 mM 
hepcidin-25 DDM TALON 10 20
Crystal Screen 
I&II vapor diffusion
Rho-zFpn-His + 0.16 mM 
hepcidin-25 DDM TALON 10 20 Memfac vapor diffusion
Rho-zFpn-His + 0.16 mM 
hepcidin-25 DDM TALON 10 20 PEG Ion vapor diffusion
Rho-zFpn-His + 0.16 mM 
hepcidin-25 DDM TALON 10 20 Wizard I&II vapor diffusion
Rho-zFpn-His + 0.16 mM 
hepcidin-25 DDM TALON 10 20 Index vapor diffusion
Rho-hFpn-His-FLAG DDM TALON-FLAG 9 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG DDM TALON-FLAG 9 20 Index fluidigm
Rho-hFpn-His-FLAG DDM TALON-FLAG 9 20 Memfac fluidigm
Rho-hFpn-His-FLAG DDM TALON-FLAG 9 20 Nextal PEG fluidigm
Rho-hFpn-His-FLAG + 0.14 
mM hepcidin-25 DDM TALON-FLAG 9 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG + 0.14 
mM hepcidin-25 DDM TALON-FLAG 9 20 Index fluidigm
Rho-hFpn-His-FLAG + 0.14 
mM hepcidin-25 DDM TALON-FLAG 9 20 Memfac fluidigm
Rho-hFpn-His-FLAG + 0.14 
mM hepcidin-25 DDM TALON-FLAG 9 20 Nextal PEG fluidigm
Rho-mFpn-His-FLAG DDM TALON-FLAG 7.5 20 Wizard I&II fluidigm
Rho-mFpn-His-FLAG DDM TALON-FLAG 7.5 20 Index fluidigm
Rho-mFpn-His-FLAG DDM TALON-FLAG 7.5 20 Memfac fluidigm
Rho-mFpn-His-FLAG DDM TALON-FLAG 7.5 20 Nextal PEG fluidigm
Rho-zFpn-His-FLAG DDM TALON-FLAG 5.2 20 Wizard I&II fluidigm
Rho-zFpn-His-FLAG DDM TALON-FLAG 5.2 20 Index fluidigm
Rho-zFpn-His-FLAG DDM TALON-FLAG 5.2 20 Memfac fluidigm
Rho-zFpn-His-FLAG DDM TALON-FLAG 5.2 20 Nextal PEG fluidigm
Rho-hFpn-His-FLAG CHAPS TALON-FLAG 4 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 CHAPS TALON-FLAG 4 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG CHAPS TALON-FLAG 4 20 Index fluidigm
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 CHAPS TALON-FLAG 4 20 Index fluidigm
Rho-hFpn-His-FLAG CHAPS TALON-FLAG 4 20
Crystal Screen 
I&II fluidigm
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Construct Detergent Purification Conc.  (mg/mL)
Temp. 
(ºC) Screen Method
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 CHAPS TALON-FLAG 4 20
Crystal Screen 
I&II fluidigm
Rho-hFpn-His-FLAG cymal-6 TALON-FLAG 4 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 cymal-6 TALON-FLAG 4 20 Wizard I&II fluidigm
Rho-hFpn-His-FLAG cymal-6 TALON-FLAG 4 20 Index fluidigm
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 cymal-6 TALON-FLAG 4 20 Index fluidigm
Rho-hFpn-His-FLAG cymal-6 TALON-FLAG 4 20
Crystal Screen 
I&II fluidigm
Rho-hFpn-His-FLAG + 0.06 
mM hepcidin-25 cymal-6 TALON-FLAG 4 20
Crystal Screen 
I&II fluidigm
Rho-hFpn-His-FLAG DDM TALON-FLAG-SEC 9 20 MacKinnon #1 vapor diffusion
Rho-hFpn-His-FLAG DDM TALON-FLAG-SEC 9 20 MacKinnon #2 vapor diffusion
Rho-mFpn-His-FLAG DDM TALON-FLAG-SEC 8 20 MacKinnon #3 vapor diffusion
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